File COPY

10/687,164 Het

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:39:19 ON 16 NOV 2005

=> file reg
=>
Uploading C:\Program Files\Stnexp\Queries\c10687164.str
```




```
chain nodes :
7  8  9  12  13  15  22  23  24  25  26  27  28
ring nodes :
1  2  3  4  5  6  16  17  18  19  20  21
chain bonds :
1-27  2-26  3-9  4-28  5-13  6-12  7-9  7-8  7-20  15-17  16-25  18-23  19-22
21-24
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21
exact/norm bonds :
3-9  5-13  6-12  7-9  7-8  15-17
exact bonds :
1-27  2-26  4-28  7-20  16-25  18-23  19-22  21-24
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21
isolated ring systems :
containing 1 :


G1:H,X,Ak,O

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  12:CLASS
 13:CLASS  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom  22:CLASS
23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
Generic attributes :
15:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic



L1      STRUCTURE UPLOADED
```

```
=>  dis l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 H,X,Ak,O
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam

L2            0 SEA SSS SAM L1

=> s l1 full
L3          630 SEA SSS FUL L1

=> file caplus
=> s l3
L4          129 L3

=> s l4 and pd<nov 2003
      23731900 PD<NOV 2003
                 (PD<20031100)
L5          90 L4 AND PD<NOV 2003

=> dis l5 1-90 bib abs hitstr

L5   ANSWER 1 OF 90  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2003:491222  CAPLUS
DN   139:69258
TI   Preparation of pyrazolopyridine derivatives as Edg-5 receptor antagonists
IN   Ozawa, Koichi; Hirata, Kazuyuki; Yamamoto, Kazuhiko
PA   Japan Tobacco Inc., Japan
SO   PCT Int. Appl., 198 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2003051876        A1    20030626    WO 2002-JP13059         20021213 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
```

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2001-382398 A 20011214
JP 2002-225343 A 20020801

OS MARPAT 139:69258

GI



I



II

AB The title pyrazolopyridine derivs. with general formula of I [wherein R1 = H, (halo)alkyl, (un)substituted aryl, aralkyl, or COR7; R7 = alkyl, alkoxy, (un)substituted aryl, aralkyl, aryloxy, or aralkyloxy; R2 = H, (un)substituted alkyl, or aryl; R3 = H, alkoxy, alkoxy-CO, haloalkyl, cycloalkyl, (un)substituted alkyl, or aryl; R4 = H or (un)substituted alkyl; R5 = H, (cyclo)alkyl, alkoxy, alkoxy-CO, carboxy, alkynyl, halo, CN, NO2, haloalkyl, alkylamino, dialkylamino, acyl, OH, (un)substituted aryloxy, aralkyloxy, aryl, aralkyl, heterocyclyl, alkoxyalkyl, or CONHR8; R8 = (un)substituted aryl or aralkyl; R6 = H, (cyclo)alkyl, alkoxy, alkoxy-CO, carboxy, alkynyl, halo(alkyl), CN, NO2, alkylamino, dialkylamino, acyl, OH, (un)substituted aryloxy, aralkyloxy, aryl, aralkyl, heterocyclyl, alkoxyalkyl, or CONHR8; X = O, -N=, -CH=, (un)substituted -NH-, or -CH2-; Y = =N-, -CH2-, =CH-, -O-, -CO-, a bond, or (un)substituted -NH-; Z = CO, CS, CH2, O, or a bond; W = O, CO, CONH, CH2, NHCH2, a bond, or (un)substituted -NH-; ring A = aryl, heterocyclyl, or cycloalkyl] and prodrugs and pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a multi-step synthesis. II showed IC50 of 0.014 μM against hAGR16 in cow. I act specifically on endothelial differentiation sphingolipid G-protein-coupled (Edg) 5 which is a sphingosine-1-phosphate receptor and, therefore, are useful as remedies for fibrosis, arteriosclerosis, coronary vasospasm, asthma, nephritis, nerve disorder, peripheral nerve disorder, rheumatoid arthritis, systemic lupus erythematosus (SLE), cancer, etc.

IT **549523-79-7P 549523-81-1P 549524-22-3P**
549524-23-4P 549524-67-6P 549524-68-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolopyridine derivs. as Edg-5 receptor antagonists)

RN 549523-79-7 CAPLUS
CN Hydrazinecarboxamide, N-[2-chloro-6-[4-[(phenylamino)carbonyl]phenyl]-4-pyridinyl]-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 549523-81-1 CAPLUS
CN Hydrazinecarboxamide, N-[2-chloro-6-[4-[(phenylamino)carbonyl]phenyl]-4-pyridinyl]-2-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 549524-22-3 CAPLUS
CN Hydrazinecarboxamide, 2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-N-[2-[4-[(phenylamino)carbonyl]phenyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 549524-23-4 CAPLUS
CN Hydrazinecarboxamide, N-[2-[4-[(phenylamino)carbonyl]phenyl]-4-thiazolyl]-2-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 549524-67-6 CAPLUS
CN Hydrazinecarboxamide, N-[5-chloro-4-[4-[(phenylamino)carbonyl]phenyl]-2-thienyl]-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 549524-68-7 CAPLUS
CN Hydrazinecarboxamide, N-[5-chloro-4-[4-[(phenylamino)carbonyl]phenyl]-2-thienyl]-2-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:363235 CAPLUS
DN 139:381850
TI Synthesis and characterization of α,ω-bis(maleimide-ester) and α,ω-bis(maleimide-amide) substituted polysiloxanes
AU Cernenco, Undina; Pinteala, Mariana; Harabagiu, Valeria; Sava, Mitica; Simionescu, Bogdan C.
CS Department of Macromolecules, "Gh. Asachi" Technical University, Iasi, 6600, Rom.
SO Revue Roumaine de Chimie (**2002**), Volume Date 2003, 47(3-4), 257-262
CODEN: RRCHAX; ISSN: 0035-3930
PB Editura Academiei Romane
DT Journal
LA English
AB Organofunctional polysiloxanes containing end aromatic ester or amide groups were synthesized by the hydrosilation of ring substituted styrene with hydrogen terminated polydimethylsiloxane (HPDMS) followed by chemical transformation of the resulting products. End phenylmaleimide groups were attached to the siloxane chains by coupling of -Ar-OH or -Ar-NH2 functionalized polysiloxanes with N-(p-carboxyphenyl)maleimide chloride. The structures of intermediate and final compds. were confirmed by IR and 1H-NMR spectroscopy and the thermal behavior was evidenced by DSC.
IT **625104-86-1P 625104-94-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and characterization of α,ω-bis(maleimide-ester) and α,ω-bis(maleimide-amide) substituted polysiloxanes)
RN 625104-86-1 CAPLUS
CN Poly[oxy(dimethylsilylene)], α-[[2-[4-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzoyl]amino]phenyl]ethyl]dimethylsilyl]-ω-[[[2-[4-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzoyl]amino]phenyl]ethyl]dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 625104-94-1 CAPLUS
CN Benzamide, N,N'-[(1,1,3,3-tetramethyl-1,3-disiloxanediyl)bis(2,1-ethanediyl-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:282325 CAPLUS
DN 138:321285
TI Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 1171 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003028641	A2	20030410	WO 2002-US31059	20020930 <--
	WO 2003028641	A3	20030828		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460594	AA	20030410	CA 2002-2460594	20020930 <--
	EP 1432693	A2	20040630	EP 2002-800388	20020930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005523237	T2	20050804	JP 2003-531977	20020930
PRAI	US 2001-326463P	P	20011001		
	US 2001-326758P	P	20011002		
	WO 2002-US31059	W	20020930		

OS MARPAT 138:321285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. QLYR1[Q = I, C(:NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepared Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.

IT **509134-02-5P 509134-04-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline-2,4-diamines as MCH receptor antagonists)

RN 509134-02-5 CAPLUS

CN Benzamide, N-[4-[[[4-(dimethylamino)-2-quinazolinyl]amino]methyl]phenyl]-4-(3-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 509134-01-4
CMF C28 H25 N5 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 509134-04-7 CAPLUS

CN Benzamide, N-[4-[[[4-(methylamino)-2-quinazolinyl]amino]methyl]phenyl]-4-(3-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 509134-03-6
CMF C27 H23 N5 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L5 ANSWER 4 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:261820 CAPLUS
DN 138:287978
TI Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer
IN Olsen, Helle Birk; Kaarsholm, Niels C.; Madsen, Peter; Ostergaard, Soren; Ludvigsen, Svend; Jakobsen, Palle; Petersen, Anders Klarskov; Steensgaard, Dorte Bjerre
PA Novo Nordisk A/S, Den.; Novo Nordisk Health Care AG
SO PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003027081	A2	20030403	WO 2002-DK595	20020913 <--
	WO 2003027081	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2460541	AA	20030403	CA 2002-2460541	20020913 <--
	EP 1429763	A2	20040623	EP 2002-774468	20020913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012522	A	20040810	BR 2002-12522	20020913
	CN 1558762	A	20041229	CN 2002-820340	20020913
	JP 2005508335	T2	20050331	JP 2003-530671	20020913
	US 2003229120	A1	20031211	US 2003-332541	20030514
	NO 2004001494	A	20040413	NO 2004-1494	20040413
PRAI	DK 2001-1337	A	20010914		
	US 2001-323925P	P	20010921		
	DK 2002-1066	A	20020705		
	US 2002-396051P	P	20020710		
	WO 2002-DK595	W	20020913		

OS MARPAT 138:287978
AB Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin prepns. are

disclosed. The ligands stabilize the hexamers and modify solubility in the neutral range, thus releasing insulin slowly following s.c. injection. Zinc-binding ligands A-B-C-D-X [A is a group which reversibly binds to a HisB10 Zn2+ site of an insulin hexamer; B is a linker selected from a valence bond or a chemical group GB of formula -B1-B2-CO-, -B1-B2-SO2-, -B1-B2-CH2-, or -B1-B2-NH-, where B1 is a valence bond, O, S, NH, or alkylimino and B2 is a valence bond, alk(en)(yn)ylene, (hetero)arylene, alkanedioyl, etc.; C is a fragment consisting of 0-5 neutral amino acids; D is a fragment comprising 1 to 20 pos. charged groups selected from amino or guanidino groups; X is OH, NH2 or a diamino group], including pharmaceutically-acceptable salts, isomers or racemates, are claimed. Thus, benzotriazol-5-ylcarbonyl-Gly2-Arg5-NH2 (BT-G2R5) was prepared and its effect on the pH-solubility profile of an insulin preparation is shown graphically.

IT **143330-27-2P 143330-31-8P 503828-63-5P**
503828-64-6P 503828-65-7P 503828-67-9P
503828-68-0P 503829-84-3P
RL: BCP (Biochemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(novel ligands for histidine-B10 zinc(II) sites of R-state insulin hexamer)

RN 143330-27-2 CAPLUS
CN Benzamide, N-phenyl-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 143330-31-8 CAPLUS
CN Benzoic acid, 4-[[4-(1H-tetrazol-5-yl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 503828-63-5 CAPLUS
CN Benzoic acid, 3-[[4-(1H-tetrazol-5-yl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 503828-64-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[4-(1H-tetrazol-5-yl)benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 503828-65-7 CAPLUS
CN Benzenepropanoic acid, 4-[[4-(1H-tetrazol-5-yl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 503828-67-9 CAPLUS
CN Benzamide, N-[4-(phenylmethoxy)phenyl]-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 503828-68-0 CAPLUS
CN Benzamide, N-(4-phenoxyphenyl)-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 503829-84-3 CAPLUS
CN L-Argininamide, N-[4-[[4-(1H-tetrazol-5-yl)benzoyl]amino]benzoyl]glycylgly cyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B

L5 ANSWER 5 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:977601 CAPLUS
DN 138:55972
TI Preparation of pyrimidine inhibitors of phosphodiesterase (PDE) 7
IN Guo, Junqing; Barbosa, Joseph; Pitts, William John; Carlsen, Marianne; Quesnelle, Claude; Dodier, Marco
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102313	A2	20021227	WO 2002-US19097	20020617 <--
	WO 2002102313	A3	20030403		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2450934	AA	20021227	CA 2002-2450934	20020617 <--
	US 2003162802	A1	20030828	US 2002-173442	20020617 <--
	EP 1397142	A2	20040317	EP 2002-744381	20020617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005500294	T2	20050106	JP 2003-504902	20020617
PRAI	US 2001-299287P	P	20010619		
	US 2002-355141P	P	20020208		
	US 2002-368752P	P	20020329		
	WO 2002-US19097	W	20020617		

OS MARPAT 138:55972
GI



I



II

AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted heteroaryl, heterocyclyl, aryl, aryl fused to heteroaryl or heterocyclyl; Z = halo, alkyl, aryl, etc.; J = H, halo, alkyl, etc.; L = H, halo, haloalkyl, etc.], phosphodiesterase 7 (PDE 7) inhibitors (including both selective inhibitors of PDE 7, and dual inhibitors of PDE 7 and phosphodiesterase 4) which are useful in treating T-cell mediated diseases, were prepared E.g., a multi-step synthesis of II, starting from 2-imino-4-thiobiuret and Et 2-chloroacetoacetate, was given.

IT **479231-23-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine inhibitors of phosphodiesterase (PDE) 7)

RN 479231-23-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[4-[4-[[(4-chlorophenyl)amino]carbonyl]phenyl]-6-(4-hydroxy-1-piperidinyl)-2-pyrimidinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L5 ANSWER 6 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:964190 CAPLUS
DN 138:39272
TI Preparation of 3-(oxazolylalkoxyphenyl)propionic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions
IN Gossett, Lynn Stacy; Green, Jonathan Edward; Henry, James Robert; Jones, Winton Dennis, Jr.; Matthews, Donald Paul; Shen, Quan Rong; Smith, Daryl Lynn; Vance, Jennifer Ann; Warshawsky, Alan M.
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100403	A1	20021219	WO 2002-US15143	20020524 <--
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2448552	AA	20021219	CA 2002-2448552	20020524 <--
	NZ 529550	A	20031219	NZ 2002-529550	20020524
	EP 1401434	A1	20040331	EP 2002-746380	20020524
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010167	A	20040406	BR 2002-10167	20020524
	JP 2005502600	T2	20050127	JP 2003-503224	20020524
	US 2005075378	A1	20050407	US 2003-477405	20031112
PRAI	US 2001-296701P	P	20010607		
	WO 2002-US15143	W	20020524		

OS MARPAT 138:39272
GI



I



II

AB Title compds. I [wherein n = 2-5; V = a bond or O; X = CH2 or O; p = 0 or 1; m = 1-4; Y1 = (un)substituted (hetero)aryl; Y2 and Y3 = independently H, alkyl, or alkoxy; Y4 = (un)substituted alk(en/yn)ylaminoalkyl, carboxyaminoalkyl, (thio)ureidoalkyl, carbamoylalkyl, aminoalkyl, alkoxyalkyl, alkylthioalkyl, or CN; R5 = H or alkyl; and pharmaceutically acceptable salts, solvates, hydrates, or stereoisomers thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, 3-[2-(1,3-dioxo-1,3-dihydroisoindolo-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-Bu ester was coupled with toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester in the presence of Cs2CO3 in DMF. Deprotection of the amine using NaBH4 in isopropanol followed by conversion to the carbamate and deesterification gave II. I are useful for the treatment of Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X, as well as cardiovascular diseases (no data).

IT **478543-08-7P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4-phenylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478543-08-7 CAPLUS

CN Benzenepropanoic acid, 2-[[[(1-methylethoxy)carbonyl]amino]methyl]-4-[2-[5-methyl-2-[4-[(phenylamino)carbonyl]phenyl]-4-oxazolyl]ethoxy]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:173838 CAPLUS
DN 137:47531
TI Synthesis and properties of novel aromatic polyamides based on 4-aryl-2,6-bis(4-chlorocarbonylphenyl) pyridines
AU Tamami, Bahman; Yeganeh, Hamid
CS College of Science, Department of Chemistry, Shiraz University, Shiraz, 71454, Iran
SO European Polymer Journal (**2002**), 38(5), 933-940
CODEN: EUPJAG; ISSN: 0014-3057
PB Elsevier Science Ltd.
DT Journal
LA English
AB A facile synthesis of three new diacid chlorides containing pyridine ring bearing aromatic type pendant groups on its 4-position is described. The monomers were characterized by FTIR, 1HNMR, mass spectroscopies and elemental anal. Polycondensation reactions of the prepared diacid chlorides with different com. available diamines resulted in the preparation of novel polyamides. Optimal conditions for polyamidations were obtained via study of the model compds. The polymers were characterized by FTIR, 1HNMR, and elemental anal. and their phys. properties including solution viscosity, solubility properties, thermal stability and thermal behavior were studied as well. The polyamides show excellent thermal stability and solubility in polar aprotic solvents.
IT **438628-26-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(model compound; synthesis and properties of aromatic polyamides based on 4-aryl-2,6-bis(4-chlorocarbonylphenyl) pyridines)
RN 438628-26-3 CAPLUS
CN Benzamide, 4,4'-[4-(4-methoxyphenyl)-2,6-pyridinediyl]bis[N-phenyl- (9CI) (CA INDEX NAME)



IT **438628-42-3P 438628-43-4P 438628-46-7P**
438628-47-8P 438628-50-3P 438628-51-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and properties of aromatic polyamides based on 4-aryl-2,6-bis(4-chlorocarbonylphenyl) pyridines)

RN 438628-42-3 CAPLUS

CN Poly[(4-phenyl-2,6-pyridinediyl)-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 438628-43-4 CAPLUS

CN Poly[(4-phenyl-2,6-pyridinediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 438628-46-7 CAPLUS
CN Poly[[4-(4-methoxyphenyl)-2,6-pyridinediyl]-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 438628-47-8 CAPLUS
CN Poly[[4-(4-methoxyphenyl)-2,6-pyridinediyl]-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 438628-50-3 CAPLUS
CN Poly[[4-(4-chlorophenyl)-2,6-pyridinediyl]-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 438628-51-4 CAPLUS
CN Poly[[4-(4-chlorophenyl)-2,6-pyridinediyl]-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:124764 CAPLUS
DN 136:341350
TI Gamma-radiation-induced graft copolymerization of N-[4-(N'-substituted amino carbonyl)phenyl]maleimide onto poly(vinyl chloride) films
AU Abdel-Naby, Abir S.
CS Chemistry Department, Faculty of Science, Cairo University, Fayium, 63111, Egypt
SO Journal of Vinyl & Additive Technology (**2001**), 7(4), 244-249
CODEN: JVATF4; ISSN: 1083-5601
PB Society of Plastics Engineers
DT Journal
LA English
AB Three N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide (RPhMI : N'-substituent (R) = Ph, cyclohexyl, p-chlorophenyl) were grafted onto Vestolit S 7054 poly(vinyl chloride) (PVC) films using gamma irradiation The effects of different parameters on the graft yield were investigated. These parameters included radiation dose and monomer concentration The thermal properties of the grafted polymer were investigated by the determination of dehydrochlorination rate, thermal gravimetric behavior, and UV stability.
IT **372188-61-9P 372188-64-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(gamma-radiation-induced graft copolymn. of N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide onto poly(vinyl chloride) films and thermal properties of grafted films)
RN 372188-61-9 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl-, polymer with chloroethene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



CM 2

CRN 75-01-4
CMF C2 H3 Cl



RN 372188-64-2 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with chloroethene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 372188-63-1
CMF C17 H11 Cl N2 O3



CM 2

CRN 75-01-4
CMF C2 H3 Cl



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:107327 CAPLUS
DN 136:167394
TI Preparation of carboxamide compounds and their use as antagonists of a human 11CBY receptor
IN Johnson, Christopher Norbert; Jones, Martin; O'Toole, Catherine Anne; Stemp, Geoffrey; Thewlis, Kevin Michael; Witty, David
PA Smithkline Beecham P.L.C., UK
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002010146	A1	20020207	WO 2001-EP8637	20010726	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2417638	AA	20020207	CA 2001-2417638	20010726	<--
	EP 1305304	A1	20030502	EP 2001-956562	20010726	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	BR 2001012856	A	20030701	BR 2001-12856	20010726	<--
	JP 2004505070	T2	20040219	JP 2002-515877	20010726	
	ZA 2003000262	A	20040413	ZA 2003-262	20030109	
	NO 2003000471	A	20030328	NO 2003-471	20030130	<--
	BG 107510	A	20030930	BG 2003-107510	20030130	<--
	US 2004063686	A1	20040401	US 2003-343424	20030930	
PRAI	GB 2000-18758	A	20000731			
	GB 2001-12544	A	20010523			
	WO 2001-EP8637	W	20010726			

OS MARPAT 136:167394
GI



I



II

AB Title compds. [I; A = H, C1-6alkyl optionally substituted by hydroxyl, C1-6alkoxy, C1-6alkenyl, C1-6 acyl, halogeno, OH, CN, CF3; R3 = H, CH3, CH3CH2; R4 = aromatic carbocycle, heterocycle; Z = O, S, NH, CH2, single bond, at the 3 or 4 position of R4 relative to the carbonyl group; R5 = aromatic carbocycle, heterocycle; Q = XYNR1R2; X = O, S; Y = C2-4 alkylene, C5-6 cycloalkylene; R1, R2 independently = C1-6 alkyl, phenyl-C1-6 alkyl; R1R2 = 5-, 6-, 7-membered ring optionally containing one or more heteroatom selected from O, S, N; etc.], pharmaceutically acceptable salts, and solvate are prepared and as antagonists of a human 11CBY receptor. Title compds. and pharmaceutical composition are useful in the treatment and/or prophylaxis of one or more of the disorder, such as, major depression, manic depression, anxiety, etc. Thus, the title compound II was prepared from 2'-methyl-biphenyl-4-carboxylic acid and 4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine in DMF in the presence of 1-(3-dimethylaminopropyl)-3-Et carbodiimide hydrochloride and 1-hydroxy-7-azabenzotriazole.

IT **395677-15-3P 395677-18-6P 395677-21-1P**
395677-25-5P 395677-26-6P 395677-37-9P
395677-38-0P 395678-28-1P 395678-29-2P
395678-30-5P 395678-32-7P 395678-36-1P
395678-37-2P 395678-39-4P 395678-42-9P
395678-43-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxamide compds. as antagonists of human 11CBY receptor)

RN 395677-15-3 CAPLUS

CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 395677-18-6 CAPLUS
CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 395677-21-1 CAPLUS
CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 395677-25-5 CAPLUS
CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 395677-26-6 CAPLUS

CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(1-methyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 395677-37-9 CAPLUS
CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 395677-38-0 CAPLUS
CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-pyrazinyl- (9CI) (CA INDEX NAME)



RN 395678-28-1 CAPLUS
CN Benzamide, N-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 395678-29-2 CAPLUS
CN Benzamide, N-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-4-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 395678-30-5 CAPLUS
CN Benzamide, N-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-4-(2-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 395678-32-7 CAPLUS
CN Benzamide, N-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-4-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 395678-36-1 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 395678-37-2 CAPLUS
CN Benzamide, 4-(6-methoxy-3-pyridinyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 395678-39-4 CAPLUS
CN Benzamide, 4-(2,4-dimethoxy-5-pyrimidinyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 395678-42-9 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(3-thienyl)-(9CI) (CA INDEX NAME)



RN 395678-43-0 CAPLUS
CN Benzamide, 4-(3-furanyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-(9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:83982 CAPLUS
DN 136:151155
TI Preparation of 3-(5-phenylthien-2-yl)oxazolidin-2-ones as cytokine inhibitors
IN Mueller, Ulrich; Schmeck, Carsten; Kretschmer, Axel; Bremm, Klaus-Dieter
PA Bayer A.-G., Germany
SO Ger. Offen., 88 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10034624	A1	20020131	DE 2000-10034624	20000717 <--
PRAI DE 2000-10034624		20000717		

OS MARPAT 136:151155
GI



I

AB Title compds. [I; R1 = CHO, (substituted) alkyl, CONR3R4; R3, R4 = H, (substituted) alkyl, aryl; or NR3R4 = (substituted) heterocyclyl, bicyclyl; R2 = OC(O)NR5R6; R5, R6 = H, (substituted) alkyl, aryl; or NR5R6 = (substituted) heterocyclyl], were prepared Thus, 4-[5-(5-hydroxymethyl-2-oxooxazolidin-3-yl)thien-2-yl]benzaldehyde (preparation given) in CH2Cl2 was stirred with 4-morpholinecarbonyl chloride and phosphazene base P4-t-Bu for 18 h at 23° to give 84% 2-oxo-3-[5-(4-formylphenyl)thien-2-yl]-5-[(4-morpholinyl)carbonyloxymethyl]oxazolidine. Several I tested by an enzyme-linked immuno sorbent assay (ELISA) gave 50% TNF-α biosynthesis inhibition with EC50 = 4.8-16,000 nM in human blood monocytes.

IT **393086-21-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (phenylthienyl)oxazolidinones as cytokine inhibitors)

RN 393086-21-0 CAPLUS
CN 4-Morpholinecarboxylic acid, [3-[5-[4-[[(4-methoxyphenyl)amino]carbonyl]phenyl]-2-thienyl]-2-oxo-5-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:851793 CAPLUS
DN 136:5986
TI Preparation of azole inhibitors of cytokine production
IN Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Sciotti, Richard J.; Wagenaar, Frank L.
PA USA
SO U.S. Pat. Appl. Publ., 124 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2001044445	A1	20011122	US 1999-289155	19990408 <--
PRAI US 1999-289155		19990408		

OS MARPAT 136:5986
GI



I



II

AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph, the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) production and cellular proliferation in stimulated human T cell lines or human

peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepared General procedures for preparation of compds. I were described. Thus, the title compound II was prepared

IT **245744-77-8P 245744-83-6P 245746-31-0P 245746-38-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole inhibitors of cytokine production)

RN 245744-77-8 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 245744-83-6 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 245746-31-0 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 245746-38-7 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-cyanophenyl)-

(9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:676775 CAPLUS
DN 135:211059
TI Preparation of arylheterocycle phosphates as antidiabetics and aryl fructose-1,6-bisphosphatase inhibitors
IN Bookser, Brett C.; Dang, Qun; Reddy, K. Raja
PA Metabasis Therapeutics, Inc., USA
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001066553	A2	20010913	WO 2001-US7452	20010307	<--
	WO 2001066553	A3	20020314			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	CA 2401706	AA	20010913	CA 2001-2401706	20010307	<--
	US 2002040014	A1	20020404	US 2001-801933	20010307	<--
	US 6919322	B2	20050719			
	BR 2001009062	A	20021126	BR 2001-9062	20010307	<--
	EP 1265907	A2	20021218	EP 2001-918456	20010307	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2003525944	T2	20030902	JP 2001-565369	20010307	<--
	CN 1516705	A	20040728	CN 2001-809021	20010307	
	ZA 2002007004	A	20031201	ZA 2002-7004	20020830	
	NO 2002004240	A	20021108	NO 2002-4240	20020905	<--
	US 2005176684	A1	20050811	US 2005-43859	20050125	
PRAI	US 2000-187750P	P	20000308			
	US 2001-801933	A3	20010307			
	WO 2001-US7452	W	20010307			

OS MARPAT 135:211059
GI



I

AB Novel FBPase inhibitors of formula (R1Y)2P(O)LR wherein R is substituted aryl; L is furanyl, thienyl, pyridyl, oxazolyl, imidazolyl, Ph, pyrimidinyl, pyrazinyl, alkynyl; Y is independently O, amine, ketone; R1 is H, alkyl, aryl, alicyclic, are useful in the treatment of diabetes and other conditions associated with elevated blood glucose. Thus, furan phosphate I was prepared and tested in vivo as antidiabetics and aryl fructose-1,6-bisphosphatase inhibitor (IC50 = 0.31 μM).

IT **358671-43-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylheterocycle phosphates as antidiabetics and aryl fructose-1,6-bisphosphatase inhibitors)

RN 358671-43-9 CAPLUS

CN Phosphonic acid, [5-[4-[[[3-(hydroxymethyl)phenyl]amino]carbonyl]phenyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:662204 CAPLUS

DN 135:358511

TI γ-Radiation-induced graft copolymerization of N-[4-(N' substituted amino carbonyl)phenyl]maleimide onto poly(vinyl chloride) films

AU Abdel-Naby; Abir, S.

CS Chemistry Department, Faculty of Science, Cairo University, Fayium, 63111, Egypt

SO Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (**2001**), 42(2), 820-821
CODEN: ACPPAY; ISSN: 0032-3934

PB American Chemical Society, Division of Polymer Chemistry

DT Journal; (computer optical disk)

LA English

AB Three types of N[4-(N'-substituted amino carbonyl)phenyl]maleimide - RPhMI : N-substituent (R)=phenyl, cyclohexyl, p-chlorophenyl were grafted onto poly(vinyl chloride) (PVC) films using gamma radiation. The effects of

different parameters on the grafted polymer yield have been investigated. These parameters include radiation dose and monomer concentration Thermal properties of the grafted polymeric films have been investigated by the determination of dehydrochlorination rate, thermal gravimetric anal., and UV radiation.

IT **372188-61-9P 372188-64-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(γ-radiation-induced graft copolymn. of N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide onto poly(vinyl chloride) films)

RN 372188-61-9 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl-, polymer with chloroethene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



CM 2

CRN 75-01-4
CMF C2 H3 Cl

$H_2C{=}CH{-}Cl$

RN 372188-64-2 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with chloroethene, graft (9CI) (CA INDEX NAME)

CM 1

CRN 372188-63-1
CMF C17 H11 Cl N2 O3



CM 2

CRN 75-01-4
CMF C2 H3 Cl

$H_2C{=}CH{-}Cl$

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:657511 CAPLUS
DN 135:195569
TI Preparation of 4-[1,6-dihydro-(6H)-6-oxo-3-pyridazinyl]benzoic acid amides and esters for treatment of anemia.
IN Stoltefuss, Juergen; Loegers, Michael; Braeunlich, Gabriele; Schmeck, Carsten; Nielsch, Ulrich; Stuermer, Werner; Gerdes, Christian; Lustig, Klemens; Sperzel, Michael
PA Bayer A.-G., Germany
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10010422	A1	20010906	DE 2000-10010422	20000303 <--
PRAI	DE 2000-10010422		20000303		

OS MARPAT 135:195569
GI



I

AB Title compds. [I; A, D, E, G = H, halo, CF3, OH, alkyl, alkoxy; R1, R2 = H, alkyl; R3 = OR4, NR5R6; R4 = vinyl, allyl, (substituted) cycloalkyl, alkyl, aryl; R5 = H, alkyl; R6 = cycloalkyl, tetrahydrobenzothienyl, (substituted) aryl, heterocyclyl, alkyl; R5R6 = tetrahydro(iso)quinolinyl, morpholinyl, imidazolyl, piperidinyl], were prepared as erythropoiesis stimulators (no data). Thus, 4-[1,6-dihydro-(6H)-6-oxo-3-pyridazinyl]benzoic acid imidazolide (preparation given) was refluxed with 2,6-difluorobenzylamine in dioxane for 20 h to give 65% 4-[1,6-dihydro-(6H)-6-oxo-3-pyridazinyl]benzoic acid 2,6-difluorobenzylamide.

IT **356806-70-7P 356807-62-0P 356808-13-4P 356808-19-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxyphenylpyridazinones for treatment of anemia)

RN 356806-70-7 CAPLUS

CN Benzamide, 4-(1,6-dihydro-4-methyl-6-oxo-3-pyridazinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 356807-62-0 CAPLUS

CN Benzamide, 4-(1,6-dihydro-6-oxo-3-pyridazinyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 356808-13-4 CAPLUS

CN Benzamide, 4-(1,6-dihydro-6-oxo-3-pyridazinyl)-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 356808-19-0 CAPLUS
CN Benzamide, 4-(1,6-dihydro-6-oxo-3-pyridazinyl)-N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:636054 CAPLUS
DN 135:195563
TI Preparation of (arylsulfonamidophenyl)pyrazolamines as neuropeptide Y5 modulators for the treatment of obesity and other disorders
IN Kordik, Cheryl P.; Dax, Scott L.; Luo, Chi; Reitz, Allen B.; McNally, James J.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062737	A2	20010830	WO 2001-US6025	20010223 <--
	WO 2001062737	A3	20020314		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002065289	A1	20020530	US 2001-791203	20010222 <--
	US 6531478	B2	20030311		
	CA 2401226	AA	20010830	CA 2001-2401226	20010223 <--
	EP 1257539	A2	20021120	EP 2001-913034	20010223 <--
	EP 1257539	B1	20041229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003524003	T2	20030812	JP 2001-562519	20010223 <--
	AT 286028	E	20050115	AT 2001-913034	20010223
	ES 2236194	T3	20050716	ES 2001-1913034	20010223
PRAI	US 2000-184550P	P	20000224		

WO 2001-US6025 W 20010223
OS MARPAT 135:195563
GI



I



II

AB The title compds. (I) [wherein R1 and R2 = independently H, alkyl, sufonylamino, or (un)substituted arylsulfonyl; R3 = (un)substituted (hetero)aryl; L = (un)substituted heteroaryl or cycloalkyl; n = 0-1; X = sulfonylamino(alkyl), (un)substituted alkylaminosulfonyl, aminocarbonyl, carbonyl(amino), sulfonyl, etc.; R4 = H, alkyl, (un)substituted (hetero)aryl, aralkyl, or heterocycloalkyl; p = 0-1; R5 = H, halo, alkyl, or CF3; with provisos; and pharmaceutical compns. thereof] were prepared as ligands for the neuropeptide Y subtype 5 receptor (NPY5). For example, cycloaddn. of 2-cyano-4'-nitroacetophenone (preparation given) with p-tolylhydrazine, reduction using Pd/C, and addition of 4-methoxybenzenesulfonyl chloride gave II, which inhibited human NPY5 by 100% at 30 μM and exhibited an IC50 value of 15 nM in an in vitro competition binding assay. I are useful in the treatment of disorders and diseases associated with the NPY receptor subtype Y5, such as eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidemia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression, anxiety, cerebral hemorrhage, shock, congestive heart failure, nasal congestion, or diarrhea (no data).

IT **356778-05-7P 356778-06-8P 356778-07-9P 356778-16-0P 356778-17-1P 356778-18-2P 356778-34-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (arylsulfonamidophenyl)pyrazolamine neuropeptide Y5 modulators by cycloaddn. of nitroacetophenones with hydrazines for the treatment of obesity and other disorders)

RN 356778-05-7 CAPLUS
CN Benzamide, N-phenyl-4-[1-phenyl-5-[(phenylsulfonyl)amino]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 356778-06-8 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-4-[1-phenyl-5-[(phenylsulfonyl)amino]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 356778-07-9 CAPLUS
CN Benzamide, N-(4-methylphenyl)-4-[1-phenyl-5-[(phenylsulfonyl)amino]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 356778-16-0 CAPLUS
CN Benzamide, 4-[1-(4-methylphenyl)-5-[[(4-methylphenyl)sulfonyl]amino]-1H-pyrazol-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 356778-17-1 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-4-[1-(4-methylphenyl)-5-[[(4-methylphenyl)sulfonyl]amino]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 356778-18-2 CAPLUS
CN Benzamide, N-(4-methylphenyl)-4-[1-(4-methylphenyl)-5-[[(4-methylphenyl)sulfonyl]amino]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 356778-34-2 CAPLUS
CN Benzamide, 4-[5-amino-1-(4-methylphenyl)-1H-pyrazol-3-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:628987 CAPLUS
DN 136:171
TI Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor
AU Kordik, C. P.; Luo, C.; Zanoni, B. C.; Dax, S. L.; McNally, J. J.; Lovenberg, T. W.; Wilson, S. J.; Reitz, A. B.
CS Drug Discovery Division, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SO Bioorganic & Medicinal Chemistry Letters (**2001**), 11(17), 2283-2286
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB 1,3-Disubstituted-5-aminopyrazoles were prepared based on a lead compound found through high-throughput screening of our corporate compound library in an assay measuring affinity for the human neuropeptide Y5 receptor. The target compds. were prepared by cyclization of α-cyanoketones with appropriate hydrazines, followed by reduction and coupling to various sulfonamido-carboxylic acids. Several of these arylpyrazoles displayed high affinity for the human NPY Y5 receptor (<20 nM IC50s).

IT **356778-34-2P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(aminopyrazoles with high affinity for human neuropeptide Y5 receptor)
RN 356778-34-2 CAPLUS
CN Benzamide, 4-[5-amino-1-(4-methylphenyl)-1H-pyrazol-3-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:565039 CAPLUS
DN 135:153111
TI Preparation of aryl-amidines and derivatives, and prodrugs thereof as factor Xa inhibitors
IN Kang, Myung-Gyun; Park, Doo-Hee; Kwon, Oh-Hwan; Kim, Eunice Eun-Kyeong; Hwang, Kwang-Yeon; Heo, Yong-Seok; Park, Tae-Kyo; Lee, Tae-Hee; Moon, Kwang-Yul; Park, Jong-Woo; Chang, Hye-Kyung; Lee, Sang-Koo; Lee, Sun-Hwa; Park, Su-Kyung; Lee, Sung-Hack; Park, Hee-Dong
PA LG Chem Investment Ltd., S. Korea
SO PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001055146	A1	20010802	WO 2001-KR13	20010104 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
KR 2001076973	A	20010817	KR 2000-4458	20000129 <--
KR 2001081202	A	20010829	KR 2000-6354	20000211 <--
KR 2001081598	A	20010829	KR 2000-7487	20000217 <--
KR 2001081600	A	20010829	KR 2000-7489	20000217 <--
EP 1254136	A1	20021106	EP 2001-901571	20010104 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523356	T2	20030805	JP 2001-561005	20010104 <--

	US 2003065176	A1	20030403	US 2002-181975	20020724 <--
	KR 2002070385	A	20020906	KR 2002-709662	20020726 <--
PRAI	KR 2000-4458	A	20000129		
	KR 2000-6354	A	20000211		
	KR 2000-7487	A	20000217		
	KR 2000-7489	A	20000217		
	WO 2001-KR13	W	20010104		

OS MARPAT 135:153111

GI



AB The aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula G-A(D)-A-L-P[(X)n]-Q(Y)Z [wherein Ar = benzene, pyridine, thiophene, naphthalene, isoquinoline; G = R, F, Cl, Br, iodo, cyano, OR, O2CR, CO2R, CONR2 (wherein R = H, linear, branched, cyclic or branched cyclic C1-10 alkyl); A = Q-Q6, CH2 CHR5CONH, CH2CHR5CH2O, CH2CHR6NHCO [wherein R1, R2 = F, Cl, Br, iodo, R, CH2O R, CH2O2CR, CO2R, CONR2, CON(CH2)m (m = 2-7), CO-morpholine, etc.; R3 = group listed in R2, CONH(amino acid or its ester or amide), etc.; R4 = F, Cl, Br, iodo, cyano, OR, R; R5 = NR2, NR(COR), NR (CH2)m1 CO2R (m1 = 0-3), etc.; R6 = CO2R, CONR2, CH2OR]; Lb= CONH, CONHCH2, CH2NHCO, NHCONH, etc.; D = NH2, CH2NH2, C(:NR7)NH2 (wherein R7 = H, OH, CO2R8, OR8, O2COR8; wherein R8 = Ph, CH2Ph, linear, branched, cyclic or branched cyclic C1-10 alkyl); L = (CH2)m2 (m2 = 0,1); P = benzene, pyridine, pyrrole, furan, thiophene, oxazole, isoxazole, imidazole, 1,2-diazole, thiazole, isothiazole, pyridazine, pyridazine, pyrimidine, pyrazine, naphthalene, etc.; n = 0-2; Q = H, benzene, pyridine, pyridine, pyrrole, furan, thiophene, oxazole, isoxazole, imidazole, 1,2-diazole, thiazole, isothiazole, etc.; Y, Z = R, F, Cl, Br, iodo, cyano, OR, CO2R, COR, CONR2, NR2, NR(COR), N(COR)2, CF3, OCF3, etc.], pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isomers thereof are prepared These compds. are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the above compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders. N-[4-(2-

aminosulfonylphenyl)phenyl]-cis-2-(3-aminoiminomethylphenyl)cyclopropane-1-carboxamide monotrifluoroacetate, 4-(4-aminoiminomethylbenzyl)-1-(3-aminoiminomethylbenzyl)pyrrole-3-carboxamide bis(trifluoroacetate), 3-aminoiminomethylbenzyl 2-(3-aminoiminomethylphenyl)benzyl ether bis(trifluoroacetate), and (S)-N-{4-(2-aminosulfonylphenyl)benzoyl}-3-(3-aminoiminomethylphenyl)alanine Et ester trifluoroacetate in vitro inhibited FXa with Ki of 0.5, 0.12, 0.44, and 2 nM, resp., and thrombin with Ki of 2,900, 2.1, 5, and 620, resp., and exhibited the thrombin/FXa selectivity of 5,800, 18, 11, and 310, resp.

IT **352616-84-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aryl-amidines and derivs., and prodrugs thereof as factor Xa inhibitors and anticoagulants for treatment of thrombosis disorders)

RN 352616-84-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 1-[(3-cyanophenyl)methyl]-4-[4-[(phenylamino)carbonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:564832 CAPLUS
DN 135:147457
TI Pharmaceutical compositions containing anti-β1-integrin compounds, their preparation, and their use in inhibiting cell adhesion
IN Zheng, Zhongli; Cuervo, Julio H.; Lin, KoChung; Ateeq, Humayun Saleem
PA Biogen, Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2001054690 A1 20010802 WO 2001-US2783 20010126 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1253923 A1 20021106 EP 2001-905160 20010126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2003114514 A1 20030619 US 2002-202740 20020725 <--
PRAI US 2000-178585P P 20000128
WO 2001-US2783 W 20010126
OS MARPAT 135:147457
AB Organic Anti-β1-integrin compds. useful for inhibiting cell-adhesion are disclosed. Pharmaceutical compns. containing the compds. are included, as is compound preparation
IT **352275-38-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-β1-integrin compds., pharmaceutical compns., preparation, and use in inhibiting cell adhesion)
RN 352275-38-8 CAPLUS
CN L-Phenylalanine, 1-(methylsulfonyl)-L-prolyl-4-[[4-(5-acetyl-2-thienyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:545674 CAPLUS
DN 135:137516
TI Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases
IN Bender, Steven Lee; Bhumralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 237 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053274	A1	20010726	WO 2001-US1723	20010119 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394703	AA	20010726	CA 2001-2394703	20010119 <--
	US 2002103203	A1	20020801	US 2001-764306	20010119 <--
	US 6635641	B2	20031021		
	EP 1252146	A1	20021030	EP 2001-906592	20010119 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008025	A	20021105	BR 2001-8025	20010119 <--
	JP 2003529558	T2	20031007	JP 2001-553276	20010119 <--
	US 2004092747	A1	20040513	US 2003-621979	20030717
PRAI	US 2000-177059P	P	20000121		
	US 2001-764306	A3	20010119		
	WO 2001-US1723	W	20010119		

OS MARPAT 135:137516
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH2, O, S, NH; Y = CH2, O, S, provided at least one of X and Y = CH2 or X and Y form a cyclopropyl ring; R2-3 = H, Me, halo, CF3, CN; R4 = CONHR5, NHCOR6; where R5 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R6 = (un)substituted aryl, heteroaryl, cycloalkyl, etc] are prepared Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptobenzoic acid was treated with α-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a β-thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μM and had Ki = 2.21 nM for VEGF-R2Δ50. Treatment of cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.

IT **351323-57-4P 351324-09-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of heteroarylbenzamides used for inhibiting protein kinases)

RN 351323-57-4 CAPLUS

CN Benzamide, 4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-N-[3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 351324-09-9 CAPLUS

CN Benzamide, N-[3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]phenyl]-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:366093 CAPLUS

DN 134:361366

TI Amides as apolipoprotein A-I expression stimulators

IN Yamamori, Teruo; Nagata, Kiyoshi; Ishizuka, Natsuki; Sakai, Katsunori

PA Shionogi and Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 40 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001139550	A2	20010522	JP 1999-326416	19991117 <--
PRAI	JP 1999-326416		19991117		

OS MARPAT 134:361366

GI



I

AB The stimulators, useful for treatment of arteriosclerosis and blood lipid disorder, comprise I [A = (un)substituted mono or dicyclic aromatic hydrocarbyl, heterocyclyl, etc.; Ar1 = (un)substituted mono or dicyclic aromatic hydrocarbyl, heterocyclyl; R = H, (un)substituted lower alkyl; Z = O, S; Y1, Y2 = H, halo, (un)substituted lower alkyl, CO2H, (un)substituted lower alkoxycarbonyl, cyano, etc.; n = 0-2; dotted line represents optional double bond], their prodrug, pharmaceutically acceptable salts, or hydrates. P-toluidine was reacted with p-chlorobenzoyl chloride in the presence of pyridine in CHCl3 at room temperature for 5 h to give 81.6% 4-chloro-N-(4-tolyl)benzamide showing good stimulating activity for promoting human apolipoprotein A-I production gene.

IT **254429-90-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amides as apolipoprotein A-I expression stimulators)

RN 254429-90-8 CAPLUS

CN Benzamide, N-[4-(1-methylethyl)phenyl]-4-(1,2,3-thiadiazol-4-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:12427 CAPLUS

DN 134:86265

TI Preparation of 6-carboxyphenyldihydropyridazinones for treatment of anemia.

IN Stoltefuss, Jurgen; Braunlich, Gabriele; Logers, Michael; Schmeck, Carsten; Nielsch, Ulrich; Bechem, Martin; Gerdes, Christian; Sperzel,

Michael; Lustig, Klemens; Sturmer, Werner
PA Bayer Aktiengesellschaft, Germany; et al.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000589	A1	20010104	WO 2000-EP5564	20000616 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19929782	A1	20010104	DE 1999-19929782	19990629 <--
	CA 2377117	AA	20010104	CA 2000-2377117	20000616 <--
	EP 1196392	A1	20020417	EP 2000-945764	20000616 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503391	T2	20030128	JP 2001-506999	20000616 <--
	US 6867206	B1	20050315	US 2002-18927	20020410
PRAI	DE 1999-19929782	A	19990629		
	WO 2000-EP5564	W	20000616		

OS MARPAT 134:86265
GI



I

AB Title compds. [I; A, D, E, G = H, halo, CF3, OH, alkyl, alkoxy; R1, R2 = H, alkyl; R3 = OR4, NR5R6; R4 = vinyl, allyl, (substituted) cycloalkyl, alkyl, aryl; R5 = H, alkyl; R6 = (substituted) cycloalkyl, aryl, heteroaryl, tetrahydrobenzothienyl], were prepared as erythropoiesis stimulators (no data). Thus, 4-(4-methyl-1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)benzoic acid imidazolide (preparation given) was stirred with 2-thienylethylamine in dioxane at 100° for 5 h to give 63.8% 4-(4-methyl-1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)benzoic acid 2-(2-thienylethyl)amide.

IT **316819-95-1P 316820-03-8P 316820-04-9P 316820-10-7P 316820-28-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-carboxyphenyldihydropyridazinones for treatment of anemia)

RN 316819-95-1 CAPLUS
CN Benzamide, N-phenyl-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- (9CI) (CA

INDEX NAME)



RN 316820-03-8 CAPLUS
CN Benzamide, N-(4-methylphenyl)-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 316820-04-9 CAPLUS
CN Benzamide, N-(3-chlorophenyl)-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 316820-10-7 CAPLUS
CN Benzamide, 4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 316820-28-7 CAPLUS
CN Benzamide, N-(3-fluorophenyl)-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:911225 CAPLUS
DN 134:71593
TI Preparation of imidazoline derivatives for the treatment of diabetes, especially type II diabetes
IN Paal, Michael; Ruehter, Gerd; Schotten, Theo
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078726	A1	20001228	WO 2000-US11881	20000619 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	GB 2351081	A1	20001220	GB 1999-14222	19990618 <--
PRAI	GB 1999-14222	A	19990618		

OS MARPAT 134:71593
GI



I



II

AB The title compds. [I; R1-R4 = H, alkyl; R1 and R3, together with the carbon atoms to which they are attached, combine to form a C3-7 carbocyclic ring and R2 and R4 = H, alkyl; R1 and R2, together with the carbon atom to which they are attached combine to form a C3-7 spirocarbocyclic ring and R3 and R4 = H, alkyl; R3 and R4, together with the carbon atom to which they are attached combine to form a C3-7 spirocarbocyclic ring and R1 and R2 = H, alkyl; R5 = H, alkyl, aryl, etc.; R6 = H, alkyl, alkoxy, etc.; R7 = H, alkyl, alkoxy, etc.; Y = NHCONH, NHCO, a bond, etc.; A = a monocyclic or bicyclic ring; R8 = H, alkyl, alkenyl, etc.; R9, R10 = H, alkyl, alkoxy, etc.], useful for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present (no data), were prepared and formulated. E.g., a multi-step synthesis of the imidazoline II.HCl was given. The compds. I are effective at 0.1-5 mg/kg/day.

IT **314240-65-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoline derivs. as antidiabetics)

RN 314240-65-8 CAPLUS

CN Benzamide, 4-(4,5-dihydro-1H-imidazol-2-yl)-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:814469 CAPLUS
DN 133:362770
TI Preparation of 1-(4-carboxamidophenyl)-2-(arylalkylthio)-4-pyrimidinones as lipoprotein associated phospholipase A2 inhibitors
IN Fenwick, Ashley Edward; Hickey, Deirdre Mary Bernadette; Ife, Robert John; Leach, Colin Andrew; Smith, Stephen Allan
PA Smithkline Beecham PLC, UK
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068208	A1	20001116	WO 2000-EP3729	20000426 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1175409	A1	20020130	EP 2000-929427	20000426 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003524628	T2	20030819	JP 2000-617188	20000426 <--
PRAI	GB 1999-10378	A	19990505		
	WO 2000-EP3729	W	20000426		

OS MARPAT 133:362770
GI



I



II

AB The title compds. (I) [wherein R1 and R2 = independently (un)substituted (hetero)aryl; R3 = (hetero)aryl; R4 = (un)substituted CH2SO2NH2, CONH2, CONHNH2, or acyl; X = O or S; Y = A1A2A3, wherein A1 and A3 = independently a bond or alkylene group and A2 = a bond or O, S, SO, SO2, CO, C:CH2, CH:CH, C.tplbond.C, CONH, NHCO, or CR5R6; R5 and R6 = independently H or alkyl; Z = CR17R18; R17 and R18 = independently H or alkyl; or CR17R18 = cycloalkyl] were prepared as inhibitors of the phospholipase A2 enzyme Lp-PLA2 for the treatment of atherosclerosis. For example, II was formed by amidation of 1-(4-carboxyphenyl)-2-(4-fluorobenzylthio)-5-(pyrimidin-5-ylmethyl)pyrimidin-4-one (preparation given) with 4-(4-nitrophenoxy)benzenamine in the presence of hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl in CH2Cl2. II and nine other preferred compds. inhibited recombinant Lp-PLA2 enzyme activity with IC50 values in the range of 10 to 40 nM.

IT **306975-16-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1-(4-carboxamidophenyl)-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(4-carboxyphenyl)-2-(arylalkylthio)-4-pyrimidinones with amines for the treatment of atherosclerosis)

RN 306975-16-6 CAPLUS

CN Benzamide, 4-[5-[(2-ethoxy-5-pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-N-[4-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



IT **306974-83-4P**, 1-(4-Phenylaminocarbonylphenyl)-2-((4-fluorobenzyl)thio)-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
306974-95-8P, 1-[4-(4-Phenoxyphenylaminocarbonyl)phenyl]-2-((4-fluorobenzyl)thio)-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
306975-07-5P, 1-[4-(4-Nitrophenoxyphenyl)aminocarbonylphenyl]-2-((4-fluorobenzyl)thio)-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
306975-09-7P 306975-18-8P 306975-20-2P
306975-25-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-carboxamidophenyl)-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(4-carboxyphenyl)-2-(arylalkylthio)-4-pyrimidinones with amines for the treatment of atherosclerosis)

RN 306974-83-4 CAPLUS

CN Benzamide, 4-[2-[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 306974-95-8 CAPLUS
CN Benzamide, 4-[2-[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 306975-07-5 CAPLUS
CN Benzamide, 4-[2-[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-N-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 306975-09-7 CAPLUS
CN Benzamide, 4-[2-[[(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]-N-[4-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 306975-18-8 CAPLUS
CN Benzamide, 4-[5-[(1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-N-[4-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 306975-20-2 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 5-[[2-[[(4-fluorophenyl)methyl]thio]-1,4-dihydro-4-oxo-1-[4-[[[4-[4-(trifluoromethoxy)phenoxy]phenyl]amino]carbonyl]phenyl]-5-pyrimidinyl]methyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 306975-25-7 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 5-[[2-[[(4-fluorophenyl)methyl]thio]-1,4-dihydro-4-oxo-1-[4-[[[4-[4-(trifluoromethoxy)phenoxy]phenyl]amino]carbonyl]phenyl]-5-pyrimidinyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:98236 CAPLUS
DN 132:151811
TI Preparation of heterocyclecarboxamides and analogs as CCR5 receptor modulators
IN Neeb, Michael J.; Bondinell, William E.; Ku, Thomas W.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006085	A2	20000210	WO 1999-US17118	19990728 <--
	WO 2000006085	A3	20000504		

	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2338697	AA	20000210	CA 1999-2338697	19990728 <--
	EP 1102535	A2	20010530	EP 1999-937586	19990728 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002521408	T2	20020716	JP 2000-561942	19990728 <--
	US 6399656	B1	20020604	US 2001-744629	20010409 <--
PRAI	US 1998-94414P	P	19980728		
	US 1998-94424P	P	19980728		
	WO 1999-US17118	W	19990728		

OS MARPAT 132:151811

GI



I

AB Title compds. were prepared Thus, 5-amino-1'-(1-methylethyl)spiro[benzofuran-3(2H),4'-piperidine] (preparation given) was amidated by 2-(2,3-dihydro-1,4-benzodioxin-2-yl)thiazole-4-carboxylic acid to give title compound I. Data for biol. activity of title compds. were given.

IT **257875-31-3P 257875-32-4P 257875-34-6P 257875-35-7P 257875-37-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclecarboxamides and analogs as CCR5 receptor modulators)

RN 257875-31-3 CAPLUS

CN Benzamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 257875-32-4 CAPLUS

CN Benzamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(3-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 257875-34-6 CAPLUS
CN Benzamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 257875-35-7 CAPLUS
CN Benzamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 257875-37-9 CAPLUS
CN Benzamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:736623 CAPLUS

DN 131:336821
TI Preparation of [(indanylamino)ethyl]phenyl]benzamides and analogs as D3 and 5-HT1A receptor ligands
IN Evanno, Yannick; Marabout, Benoit; Sevrin, Mireille; Estenne-Bouhtou, Genevieve; Dachary, Emmanuelle; Veronique, Corinne
PA Sanofi-Synthelabo, Fr.
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958477	A2	19991118	WO 1999-FR1049	19990504 <--
WO 9958477	A3	20000127		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2778658	A1	19991119	FR 1998-5935	19980512 <--
FR 2778658	B1	20000630		
AU 9935271	A1	19991129	AU 1999-35271	19990504 <--
PRAI FR 1998-5935	A	19980512		
WO 1999-FR1049	W	19990504		

OS MARPAT 131:336821
AB R3CONHC6H4(CH2CH2NR1R2)-3 [I; R1 = (methoxy-substituted) 2,3-dihydro-1H-inden-2-yl; R2 = alkyl; R3 = alkyl, (methoxy)cyclohexyl, Ph, pyridyl, etc.] were prepared Thus, N-propylindan-2-amine was amidated by 3-(O2N)C6H4CH2CO2H and the product treated with Zn/HOAc to give, after LAH treatment, R3-(RHN)C6H4CH2CH2NPrR1 (R1 = 2,3-dihydro-1H-inden-2-yl)(II; R = H) which was N-acylated by BzCl to give II (R = Bz). Data for biol. activity of I were given.
IT **250161-19-4P 250161-20-7P 250161-28-5P**
250161-29-6P 250161-33-2P 250161-40-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(indanylamino)ethyl]phenyl]benzamides and analogs as D3 and 5-HT1A receptor ligands)
RN 250161-19-4 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(5-oxazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 250161-20-7 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(1H-imidazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 250161-28-5 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 250161-29-6 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(2-furanyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 250161-33-2 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(3-furanyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 250161-40-1 CAPLUS
CN Benzamide, N-[3-[2-[(2,3-dihydro-1H-inden-2-yl)propylamino]ethyl]phenyl]-4-(5-oxazolyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 26 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:659365 CAPLUS
DN 131:271873
TI Preparation of pyrazoles and triazoles as inhibitors of cytokine production
IN Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Wagenaar, Frank L.; Sciotti, Richard J.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9951580	A1	19991014	WO 1999-US7766	19990408 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2327185	AA	19991014	CA 1999-2327185	19990408 <--
	AU 9933879	A1	19991025	AU 1999-33879	19990408 <--
	EP 1068187	A1	20010117	EP 1999-915341	19990408 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002510679	T2	20020409	JP 2000-542301	19990408 <--
PRAI	US 1998-56996	A	19980408		
	WO 1999-US7766	W	19990408		

OS MARPAT 131:271873

GI



I



II

AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R2 = H, alkyl cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2, alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepared and tested as cytokine production inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors. Thus, the title compound II was prepared

IT **245744-77-8P 245744-83-6P 245746-31-0P 245746-38-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrazoles and triazoles as inhibitors of cytokine production)

RN 245744-77-8 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 245744-83-6 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 245746-31-0 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 245746-38-7 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:426983 CAPLUS
DN 131:122860
TI Preparation of silver halide photographic emulsion and silver halide photographic material
IN Kondo, Akiya
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11184032	A2	19990709	JP 1997-349421	19971218 <--
PRAI JP 1997-349421		19971218		

OS MARPAT 131:122860
AB The title photog. emulsion is prepared by using a compound having an adsorbing group to Ag halide and a substituent capable of releasing a halide ion in its mol. after formation of the Ag halide host grains. The emulsion may be prepared in such a manner that a Ag halide growth-controlling agent is added after formation of the Ag halide host grains followed by forming a Ag halide phase on the host grains or after formation of the host grains, the emulsion containing the host grains is desalted followed by supplying the ultrafiltration-desalted Ag halide grains. A Ag halide photog. material using the emulsion is also claimed. The emulsion shows high sensitivity and low fog.
IT **223485-80-1**
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(preparation of silver halide grain using compound having silver halide-adsorbing group and halide-releasing group)
RN 223485-80-1 CAPLUS
CN Benzamide, 4-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)-N-[4-(iodoacetyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 28 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:231754 CAPLUS
DN 130:318513
TI Manufacture of silver halide photographic emulsion, photographic material, and additive for the material
IN Kondo, Akiya; Miura, Norio
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11095347	A2	19990409	JP 1997-252069	19970917 <--
PRAI	JP 1997-252069		19970917		

OS MARPAT 130:318513
AB A method of manufacturing a Ag halide emulsion is claimed, which uses a compound having an adsorbing group to Ag halides and a substituent capable of releasing halide ions in its mol. The compound may be used for forming the uppermost vicinity of Ag halide grains. A Ag halide photog. material using the emulsion and an additive having the above groups in its mol. are also claimed. The emulsion shows high sensitivity, low fog, and improved storage stability.
IT **223485-80-1**
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(photog. emulsion containing compound having Ag halide-adsorbing group and halide ion-releasing group)
RN 223485-80-1 CAPLUS
CN Benzamide, 4-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)-N-[4-(iodoacetyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 29 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:137450 CAPLUS
DN 130:267727
TI Resin-to-Resin Acyl- and Aminoacyl-Transfer Reactions Using Oxime Supports
AU Hamuro, Yoshitomo; Scialdone, Mark A.; DeGrado, William F.
CS Department of Biochemistry and Biophysics School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104-6059, USA
SO Journal of the American Chemical Society (**1999**), 121(8), 1636-1644
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
AB A convergent approach to solid-phase synthesis is described in which two fragments of a mol. are synthesized on independent supports and then condensed in a key resin-to-resin transfer reaction. This approach has been utilized for the synthesis of amides and ureas by transferring acyl groups and aminoacyl groups from p-nitrophenyl(polystyrene)ketoxime resin to amino acid-functionalized Wang resins. Oxime resin-derived esters of peptides undergo transacylation to a solution-phase nucleophilic activator which then transfers the peptide to another resin bearing a nucleophilic amine terminus, resulting in amide bond formation. Likewise, oxime resin-derived carbamates, prepared from phosgenated p-nitrophenyl(polystyrene)ketoxime resin, undergo thermolytic isocyanate liberation in solution, which reacts with a second resin bearing a nucleophilic amino terminus resulting in urea bond formation.
IT **221898-66-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptides, amides, and ureas via resin-to-resin acyl and aminoacyl transfer reactions using oxime supports)
RN 221898-66-4 CAPLUS
CN Benzamide, 4-[(4R)-2,5-dioxo-4-(phenylmethyl)-1-imidazolidinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:113657 CAPLUS
DN 130:168381
TI Preparation of tetrazole compounds as pest control agents
IN Utsunomiya, Tomohisa; Niki, Toshio; Kikuchi, Takamasa; Watanabe, Junichi; Yamagishi, Kazuhiro; Nishioka, Masanori; Suzuki, Hiroyuki; Furusato, Takashi; Miyake, Toshiro
PA Nissan Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906380	A1	19990211	WO 1998-JP3397	19980730 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9884607	A1	19990222	AU 1998-84607	19980730 <--
PRAI	JP 1997-207944	A	19970801		
	JP 1998-78718	A	19980326		
	WO 1998-JP3397	W	19980730		

OS MARPAT 130:168381
GI



S(O)g-D I

AB Tetrazole compds. represented by general formula (I) [wherein A represents an optionally C1-10 alkyl, C3-10 cycloalkyl, C2-10 alkenyl, aryl, heteroaryl, or heterocyclyl or cyano; B represents O(CH2)f, NR1(CH2)f, Si(R2R3)(CH2)f, (CR4R5)m, C(O)(CH2)f, OC(O)(CH2)f, C(:NOR6)(CH2)f, CR7:NOCH2, or S(O)n(CH2)f; f is 0 to 4; g is 0,1,or 2; m is 0 to 4; n is 0, 1 or 2; D represents NR8R9 or an optionally substituted heteroaryl; R1 represents H, C1-10 alkyl, C3-10 cycloalkyl, C1-10 haloalkyl, C2-10 alkenyl, or optionally substituted aryl or CH2Ph; R2 and R3 represents C1-6 alkyl or optionally substituted aryl; R4 and R5 represents H, halo, NO2, cyano, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 alkoxycarbonyl, or optionally substituted aryl; R6 represents H or C1-6 alkyl; R7 represents H, optionally substituted C1-10 alkyl, C3-10 cycloalkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, heterocyclyl, alkoxycarbonyl, or cyano; or R7 and A together represents an optionally C1-4 alkyl-substituted C3-6 alkylene or C3-6 alkylene optionally containing O or S; R8 and R9 represent C1-4 alkyl; or R8 and R9 together represent an optionally C1-4 alkyl-substituted C3-6 alkylene or C3-6 alkylene optionally containing O or S] are prepared These compds., when used as the active ingredient of disinfectants, fungicides, insecticides, and/or miticides, exhibits high activity at a low dose. Thus, 5-(2-phenoxyphenyl)-1H(2H)-tetrazole was stirred with N,N-dimethylsulfamoyl chloride in the presence of K2CO3 in DMF at room temperature for 2 h to give 24% 2-(dimethylsulfamoyl)-5-(2-phenoxyphenyl)-2H-tetrazole which at 500 ppm controlled Pseudoperonospora cubensis on cucumber seedlings.

IT **220428-64-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrazole compds. as pest control agents)

RN 220428-64-8 CAPLUS

CN Benzamide, 4-[2-[(dimethylamino)sulfonyl]-2H-tetrazol-5-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:21683 CAPLUS

DN 130:81526
TI Preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists
IN Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
PA Merck and Co., Inc., USA
SO U.S., 78 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5854245	A	19981229	US 1997-883108	19970626 <--
PRAI US 1997-883108		19970626		

OS MARPAT 130:81526
AB XYZAB [I; A = (un)substituted (hetero)arylene; B = O(CH2)mCO2R9, (CH2)nCO2R9, CHR8(CH2)pCO2R9, OCHR8(CH2)pCO2R9; R8 = H, OH, alkyl, alkoxy, aryl, etc.; R9 = H, (ar)alkyl, aryl, acylalkyl, etc.; X = (un)substituted heterocyclyl or -heteroaryl; Y = (un)substituted heterocyclylene or -(hetero)arylene; Z = bond, NH, CONH, CO, CH2CH2, etc.; m = 1-3; n,p = 0-3] were prepared Thus, 4-(H2N)C6H4CO2Me was cyclocondensed with HN(CH2CH2Cl)2 and the N-protected and saponified product amidated by 4-BrC6H4NH2 to give the bromobenzanilide which was condensed with CH2:CHCO2Me and the product converted in 3 addnl. steps to 4-RC6H4CONHC6H4(CH2CH2CO2H)-4 (R = piperazino). Data for biol. activity of I were given.
IT **201808-39-1P 218966-20-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists)
RN 201808-39-1 CAPLUS
CN Acetic acid, [4-[[4-(2-amino-4-pyridinyl)benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 218966-20-2 CAPLUS
CN Acetic acid, [4-[[4-(4-pyridinyl)benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **201810-37-9P 201810-39-1P 218966-33-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists)

RN 201810-37-9 CAPLUS
CN Acetic acid, [4-[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]benzoyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 201810-39-1 CAPLUS
CN Acetic acid, [4-[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 218966-33-7 CAPLUS
CN Acetic acid, [4-[[4-(4-pyridinyl)benzoyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:557653 CAPLUS
DN 129:245606
TI New poly(4-chloro)maleimides. II. Synthesis and characterization of poly[amido-amino-(4-chloro)maleimides] and poly(amido-aspartimides)
AU Gaina, C.; Gaina, V.; Stoleriu, A.; Sava, M.; Chiriac, C.
CS "Petru Poni" Institute of Macromolecular Chemistry, Iasi, RO 6600, Rom.

SO Designed Monomers and Polymers (**1998**), 1(3), 315-325
CODEN: DMPOF3; ISSN: 1385-772X
PB VSP BV
DT Journal
LA English

AB New poly[(N-amido)-3-amino-4-chloro]maleimides and poly(amido-aspartimides) were synthesized by the reaction of N-(4-chlorocarbonylphenyl)-3,4-dichloromaleimide and N-(4-chlorocarbonylphenyl)maleimide with various diamines. The structures of the resulting polymers were confirmed by IR and elemental analyses. A series of model compds. was synthesized to facilitate confirmation of the polymer structures. The polymers possess inherent viscosities in the range 0.12-0.33 dL/g, good solubility in aprotic dipolar solvents, and 5% weight loss at temps. above 290°C.

IT **213114-76-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(model compound; preparation of polyamide-polyamines from diamines and N-(4-chlorocarbonylphenyl)-3,4-dichloromaleimide or N-(4-chlorocarbonylphenyl)maleimide)

RN 213114-76-2 CAPLUS
CN Benzamide, 4-[3-chloro-2,5-dihydro-4-[(4-methylphenyl)amino]-2,5-dioxo-1H-pyrrol-1-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:503580 CAPLUS
DN 129:203323
TI Syntheses and thermostabilities of N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide polymers
AU Oishi, Tsutomu; Sase, Kazuki; Tsutsumi, Hiromori
CS Department of Applied Chemistry and Chemical Engineering, Faculty of Engineering, Yamaguchi University, Ube, 755, Japan
SO Journal of Polymer Science, Part A: Polymer Chemistry (**1998**), 36(12), 2001-2012
CODEN: JPACEC; ISSN: 0887-624X
PB John Wiley & Sons, Inc.
DT Journal
LA English
AB Three types of novel N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide (RPhMI: N-substituent (R) = Ph, cyclohexyl, and cyclododecyl) were synthesized and homopolymd. under several conditions. In the copolymns. of RPhMI (M1) with styrene (ST; M2) or Me methacrylate (MMA; M2), monomer reactivity ratios and Alfrey-Price Q-e values were determined All homopolymers decomposed without softening. The initial degradation temps. of poly(RPhMI)s were over 320°C. The glass transition temps. of RPhMI copolymers were much higher than those of N-phenylmaleimide (PhMI)-ST, PhMI-MMA, N-cyclohexylmaleimide (CHMI)-ST, and CHMI-MMA copolymers. Thermal stability of the terpolymers of RPhMI with ST and acrylonitrile (AN) was higher than that of ST-AN copolymers.
IT **211996-79-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; syntheses and thermal stabilities of N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide polymers)
RN 211996-79-1 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl- (9CI) (CA INDEX NAME)



IT **211996-82-6P 211996-85-9P 211996-86-0P**
211996-92-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(syntheses and thermal stabilities of N-[4-(N'-substituted aminocarbonyl)phenyl]maleimide polymers)
RN 211996-82-6 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



RN 211996-85-9 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



CM 2

CRN 100-42-5
CMF C8 H8

$H_2C{=}CH{-}Ph$

RN 211996-86-0 CAPLUS
CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenylbenzamide (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



CM 2

CRN 80-62-6
CMF C5 H8 O2



RN 211996-92-8 CAPLUS
CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-phenyl-, polymer with ethenylbenzene and 2-propenenitrile (9CI) (CA INDEX NAME)

CM 1

CRN 211996-79-1
CMF C17 H12 N2 O3



CM 2

CRN 107-13-1
CMF C3 H3 N



CM 3

CRN 100-42-5
CMF C8 H8



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:493329 CAPLUS
DN 129:189329
TI Preparation of 2-ethynylthiazole derivatives as leukotriene antagonists
IN Nakayama, Atsushi; Takeda, Satoshi; Machinaga, Nobuo; Ogasawara, Tomomi;

Naito, Hiroshi; Hasegawa, Masashi; Haruda, Makoto
PA Daiichi Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 121 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10195063	A2	19980728	JP 1997-286340	19971020 <--
PRAI JP 1996-278347	A	19961021		

OS MARPAT 129:189329
GI



I



II

AB The title compds. [I; R1, R2 = H, halo, (un)substituted alkyl or cycloalkyl; or R1 and R2 together form a ring; A = (un)substituted Ph, pyridyl, furyl, thienyl, benzofuranyl, benzo[b]thienyl, benzoxazolyl, benzothiazolyl, pyrido[1,2-a]pyrimidinyl, quinazolyl, benzotriazinyl, or 2H-chromenyl; G1 = O, CO, C.tplbond.C, (un)substituted NR3CO, NR4, NR5SO2, SO2NR6, CONR7, C(:CHR8), CR9:CR10; R3 - R7 = H, OH, (un)substituted alkyl; R8 = cyano, CO2H, (un)substituted alkoxycarbonyl; R9, R10 = H, halo, (un)substituted alkyl, cycloalkyl, or aryl; or R9 and R10 together form a ring; G2 = (un)substituted Ph, pyridyl, thiazolyl, isoxazolyl, thienyl, or pyrimidinyl, etc.; m, n = 0, 1; Q = CO2H, (un)substituted alkoxycarbonyl, 5-tetrazolylaminocarbonyl, (un)substituted 5-tetrazolyl, 1,2,3-triazolyl, 2,4-dioxothiazolidin-5-ylidene, or 4-oxo-2-thioxothiazolidin-5-ylidene, etc.; excluding the case where m = n = 0 and Q = CO2H or alkoxycarbonyl], which show photostability and activities of both leukotriene antagonism and inhibition of histamine release from mast cells, are prepared A therapeutic or preventive drug containing I as the active ingredient for the treatment of allergies or leukotriene and/or histamine-related diseases is claimed. Thus, 2-fluoro-4-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoic acid was refluxed with SOCl2 in the presence of DMF in PhMe for 3 h and then condensed with 3-[2-(4-cyclobutyl-2-thiazolyl)ethynyl]aniline in the presence of Et3N, followed by treatment with anisole/CF3CO2H to give the title compound, ethynylthiazole containing triazole derivative (II). II in vitro showed IC50 5.7+10-10 M for inhibiting leukotriene D4-induced contraction of guinea pig's ileum and 9.3+10-9 M for inhibiting

histamine release from rat's mast cells and in vivo inhibited leukotriene D4-induced contraction of guinea pig's air way with ID50 of 0.4 mg/kg p.o. An inhalant and capsule formulation containing II were prepared

IT **211939-53-6P 211939-59-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ethynylthiazole derivs. as leukotriene antagonists for treatment of allergy and leukotriene and/or histamine-related diseases)

RN 211939-53-6 CAPLUS
CN Benzamide, N-[3-[(4-cyclobutyl-2-thiazolyl)ethynyl]phenyl]-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 211939-59-2 CAPLUS
CN Benzamide, N-[3-[(4-cyclobutyl-2-thiazolyl)ethynyl]phenyl]-4-(2-methyl-2H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



IT **211942-48-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethynylthiazole derivs. as leukotriene antagonists for treatment of allergy and leukotriene and/or histamine-related diseases)

RN 211942-48-2 CAPLUS
CN Benzamide, N-[3-[(4-cyclobutyl-2-thiazolyl)ethynyl]phenyl]-4-[2-[(4-methoxyphenyl)methyl]-2H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L5 ANSWER 35 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:460221 CAPLUS
DN 129:136765
TI Synthesis and thermal oxidation behavior of aromatic-amide bismaleimides with glycol-type bridging groups
AU Milano, J. C.; Mekkid, S.; Vernet, J.-L.
CS Lab. Chim. Appl., Inst. Sci. Ingenieur, Univ. Toulon et du Var, La Garde, 83957, Fr.
SO European Polymer Journal (**1998**), 34(5/6), 717-721
CODEN: EUPJAG; ISSN: 0014-3057
PB Elsevier Science Ltd.
DT Journal
LA French
AB This paper describes the synthesis and characterization of five structurally different bismaleimide monomers. They were prepared by reacting p-maleimidobenzoyl chloride with dianiline-terminated oligoethylene glycols (d.p. = 1-5). The cured resins are stable up to 370°C in air atmospheric
IT **210706-95-9P 210706-96-0P 210706-97-1P 210706-98-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of oligoethylene glycol bismaleimide derivative polymers)
RN 210706-95-9 CAPLUS
CN Benzamide, N,N'-[oxybis(2,1-ethanediyloxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 210706-89-1
CMF C38 H30 N4 O9

PAGE 1-A



PAGE 1-B



RN 210706-96-0 CAPLUS
CN Benzamide, N,N'-[1,2-ethanediylbis(oxy-2,1-ethanediyloxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 210706-90-4
CMF C40 H34 N4 O10

PAGE 1-A



PAGE 1-B



RN 210706-97-1 CAPLUS
CN Benzamide, N,N'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyloxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 210706-91-5
CMF C42 H38 N4 O11

PAGE 1-A



PAGE 1-B



RN 210706-98-2 CAPLUS
CN Benzamide, N,N'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis(oxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 210706-92-6
CMF C44 H42 N4 O12

PAGE 1-A



PAGE 1-B



IT **210706-88-0P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation, thermal oxidation and attempted polymerization of)
RN 210706-88-0 CAPLUS

CN Benzamide, N,N'-[1,2-ethanediylbis(oxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **210706-89-1P 210706-90-4P 210706-91-5P 210706-92-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, thermal oxidation and polymerization of)

RN 210706-89-1 CAPLUS

CN Benzamide, N,N'-[oxybis(2,1-ethanediyloxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 210706-90-4 CAPLUS

CN Benzamide, N,N'-[1,2-ethanediylbis(oxy-2,1-ethanediyloxy-4,1-

phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 210706-91-5 CAPLUS
CN Benzamide, N,N'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyloxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 210706-92-6 CAPLUS
CN Benzamide, N,N'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis(oxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:323246 CAPLUS
DN 129:16147
TI Preparation of 5H-pyrrolo[2,1-c][1,4]-benzodiazepine-3-carboxamides as vasopressin V2 antagonists
IN Trybulski, Eugene John; Molinari, Albert John; Bagli, Jehan Framroz; Ashwell, Mark Anthony; Caggiano, Thomas Joseph
PA American Home Products Corp., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820011	A1	19980514	WO 1997-US18918	19971022 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9749097	A1	19980529	AU 1997-49097	19971022 <--
	AU 737689	B2	20010830		
	BR 9713253	A	19991103	BR 1997-13253	19971022 <--
	CN 1234801	A	19991110	CN 1997-199129	19971022 <--
	EP 1021444	A1	20000726	EP 1997-911809	19971022 <--
	EP 1021444	B1	20030924		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2001503759	T2	20010321	JP 1998-521431	19971022 <--
	NZ 335483	A	20010928	NZ 1997-335483	19971022 <--

	CA 2268327	C	20020521	CA 1997-2268327	19971022 <--
	CA 2268327	AA	19980514		
	AT 250607	E	20031015	AT 1997-911809	19971022 <--
	PT 1021444	T	20040227	PT 1997-911809	19971022
	ES 2206693	T3	20040516	ES 1997-911809	19971022
	TW 496869	B	20020801	TW 1997-86115936	19971028 <--
	ZA 9709782	A	19990430	ZA 1997-9782	19971030 <--
	MX 9904070	A	20000131	MX 1999-4070	19990430 <--
	KR 2000052978	A	20000825	KR 1999-703855	19990430 <--
PRAI	US 1996-743443	A	19961101		
	WO 1997-US18918	W	19971022		

OS MARPAT 129:16147

GI



I

AB Title compds. [I; R3 = COR; R = (4-alkyl)-1-piperazinyl, 4-(di)(alkyl)amino-1-piperidinyl, (di)(alkyl)hydrazino, etc.; R4,R5 = H, halo, alkyl, alkoxy, etc.; R6 = COZR9; R9 = aroylamino, [(arylmethyl)carbonyl]amino, etc.; Z = (un)substituted 1,4-phenylene or -pyridinediyl] were prepared Thus, 2-PhC6H4CO2H was amidated by 2,4-(MeO)(H2N)C6H3CO2Me and the saponified product used to N-acylate 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine to give I (R4 = R5 = H, R6 = COZNHCOC6H4Ph-2, Z = 3-methoxy-1,4-phenylene)(II; R3 = H) which was acylated by Cl3CCOCl and the product hydrolyzed to give II (R3 = COR)(III; R = OH). The latter was amidated by 1-methylpiperazine to give III (R = 4-methyl-1-piperazinyl). Data for biol. activity of I were given.

IT **207670-37-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5H-pyrrolo[2,1-c][1,4]-benzodiazepine-3-carboxamides as vasopressin V2 antagonists)

RN 207670-37-9 CAPLUS

CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepine-3-carboxamide, 10-[2-chloro-4-[[4-(2-pyridinyl)benzoyl]amino]benzoyl]-N-[2-(dimethylamino)ethyl]-10,11-dihydro-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **207670-47-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5H-pyrrolo[2,1-c][1,4]-benzodiazepine-3-carboxamides as vasopressin V2 antagonists)
RN 207670-47-1 CAPLUS
CN Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:79439 CAPLUS
DN 128:180423
TI Preparation and formulation of purine derivatives as antitumor agents
IN Matsuda, Akira; Sasaki, Takuma; Shuto, Akira; Uemoto, Kazuhiro
PA Toa Eiyo, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 37 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10025294	A2	19980127	JP 1997-88702	19970325 <--
PRAI JP 1996-94673	A	19960326		

OS MARPAT 128:180423

GI



I

AB The title compds. I [R1 = H, halo, etc.; R2 = H, amino; R3 = H, halo; A = H, halo, alkyl, etc.] are prepared 2-Amino-6-chloro-9-[4-(phenylmethyl)benzyl]-9H-purine (II) in vitro showed IC50 of 0.3 μg/mL against NIH3T3-Ha-ras cells (cells with Ha-ras gene). II in vitro showed IC50 of > 50 μg/mL against normal NIH3T3 cells. L-651 582, an antitumor agent currently in clin. trial, in vitro showed IC50 of 5.56 μg/mL against NIH3T3-Ha-ras cells. The angiogenesis inhibiting activities of I are more potent than that of L-651 582.

IT **203202-46-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of purine derivs. as antitumor agents)

RN 203202-46-4 CAPLUS

CN Benzamide, N-[4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]phenyl]-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 38 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:55525 CAPLUS

DN 128:128032

TI Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists

IN Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800134	A1	19980108	WO 1997-US11133	19970625 <--

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	CA 2258093	AA	19980108	CA 1997-2258093	19970625 <--
	AU 9735798	A1	19980121	AU 1997-35798	19970625 <--
	AU 721130	B2	20000622		
	EP 912175	A1	19990506	EP 1997-932307	19970625 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000514061	T2	20001024	JP 1998-504291	19970625 <--
PRAI	US 1996-20975P	P	19960628		
	GB 1997-893	A	19970117		
	WO 1997-US11133	W	19970625		

OS MARPAT 128:128032
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. X-Y-Z-A-B [I; X = (un)substituted 5-7- membered aromatic or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused aromatic or nonarom. ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered aromatic or nonarom. ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered aromatic ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused aromatic ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepared and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described.

IT **201808-39-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists)

RN 201808-39-1 CAPLUS
CN Acetic acid, [4-[[4-(2-amino-4-pyridinyl)benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **201810-37-9P 201810-39-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists)
RN 201810-37-9 CAPLUS
CN Acetic acid, [4-[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]benzoyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 201810-39-1 CAPLUS
CN Acetic acid, [4-[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:6764 CAPLUS
DN 128:102478
TI Synthesis of new aromatic polyamides by carbonylation polycondensation
AU Rusanov, A. L.; Ueda, M.; Hayakawa, A.; Khotina, I. A.; Keshtov, M. L.; Begretov, M. M.
CS Nesmeyanov Inst. Organoelement Compds., Russ. Acad. Sci., Moscow, 117813, Russia
SO Vysokomolekulyarnye Soedineniya, Seriya A i Seriya B (**1997**), 39(10), 1578-1583
CODEN: VSSBEE; ISSN: 1023-3091
PB MAIK Nauka

DT Journal
LA Russian
AB A series of new polyamides was synthesized from new aromatic dibromides and 2,2'-bis[(p-aminophenoxy)-p-phenylene]propane by carbonylation polycondensation catalyzed by palladium complexes. Some thermal properties of the resulting polymers were investigated.
IT **110651-32-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of new aromatic polyamides by carbonylation polycondensation)
RN 110651-32-6 CAPLUS
CN Poly[(2-phenyl-1H-imidazole-4,5-diyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 40 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:735912 CAPLUS
DN 128:22899
TI Preparation of arthropodicidal oxazolines and thiazolines
IN Lahm, George Philip; Stevenson, Thomas Martin
PA E. I. Du Pont de Nemours & Co., USA
SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 101,212, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5686393	A	19971111	US 1996-586797	19960201 <--
	WO 9504726	A1	19950216	WO 1994-US7459	19940729 <--
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9405784	A	19960205	ZA 1994-5784	19940803 <--
	IN 177790	A	19970222	IN 1994-CA1032	19941212 <--
	US 5767281	A	19980616	US 1997-869463	19970605 <--
PRAI	US 1993-101212	B2	19930804		
	US 1994-203060	B2	19940228		
	WO 1994-US7459	W	19940729		
	US 1996-586797	A3	19960201		

OS MARPAT 128:22899
GI



I



II

AB The title compds. [I; E = C1-4 alkyl, C1-4 haloalkyl; Z = O, S; R1 = F,

Cl; R2 = H, F, Cl; R3 = (un)substituted C2-10 alkynyl, Ph, 8-10 membered fused bicyclic ring system containing 0-4 heteroatoms, etc.; R4, R5 = H, halo, CN, etc.; q = 0-3], useful as arthropodicides, were prepared Thus, reaction of 2-(2,6-difluorophenyl)-4,5-dihydro-4-(4-iodophenyl)oxazole with 2-naphthylboronic acid in the presence of NaHCO3 and PdCl2(Ph3P)2 in dimethoxyethane/H2O afforded II which gave 80% or higher mortality levels when applied against larval two-spotted spider mites.

IT **167855-95-0P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arthropodicidal oxazolines and thiazolines)

RN 167855-95-0 CAPLUS

CN Benzamide, 4-[2-(2,6-difluorophenyl)-4,5-dihydro-4-oxazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:578778 CAPLUS

DN 127:259616

TI Photoaffinity labeling of the ligand-interacting helix of the retinoic acid receptor-α

AU Sasaki, Toru; Morisaki, Naoko; Iwasaki, Shigeo; Kagechika, Hiroyuki; Fukasawa, Hiroshi; Shudo, Koichi; Shida, Yasuo; Hashimoto, Yuichi

CS Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo, 113, Japan

SO Biological & Pharmaceutical Bulletin (**1997**), 20(8), 913-916
CODEN: BPBLEO; ISSN: 0918-6158

PB Pharmaceutical Society of Japan

DT Journal

LA English

AB Two photoaffinity-labeling probes for retinoic acid receptor (RAR) α, 4-[(3-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)carboxamido]benzoic acid (3DIAM) and its p-isomer (4DIAM), were designed and synthesized. Both compds. had high affinity for recombinant RARα (MBP-RARα/E) and bound covalently to its cognate ligand-binding site. The labeled site of MBP-RARα/E with 3DIAM was determined, by the endoproteinase combination method, to be located in helix 11 of the ligand-binding domain of RARα, which is the position at which the ligand is considered to bind, on the basis of the reported crystal structure of the retinoic acid/RARγ complex.

IT **196196-33-5P**
RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(photoaffinity labeling of ligand-interacting helix of retinoic acid receptor α)

RN 196196-33-5 CAPLUS

CN Benzoic acid, 4-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 42 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:189938 CAPLUS
DN 126:186111
TI Preparation of heterocyclic carboxylic acid derivatives as retinoid receptor agonists
IN Kikuchi, Kouichi; Tagami, Katsuya; Yoshimura, Hiroyuki; Hibi, Shigeki; Nagai, Mitsuo; Abe, Shinya; Okita, Makoto; Hida, Takayuki; Higashi, Seiko; Tokuhara, Naoki; Kobayashi, Seiichi; et al.
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9702244	A1	19970123	WO 1996-JP1782	19960627	<--
	W: AU, CA, CN, HU, KR, MX, NO, NZ, RU, US					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	JP 09071566	A2	19970318	JP 1996-141433	19960604	<--
	AU 9662422	A1	19970205	AU 1996-62422	19960627	<--
	EP 838453	A1	19980429	EP 1996-921104	19960627	<--
	EP 838453	B1	20050427			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
	AT 294160	E	20050515	AT 1996-921104	19960627	
	EP 1559709	A1	20050803	EP 2005-1823	19960627	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
	US 5977108	A	19991102	US 1997-981770	19971230	<--
	US 6329402	B1	20011211	US 1999-313087	19990517	<--
	US 2002032202	A1	20020314	US 2001-910012	20010723	<--
	US 6541474	B2	20030401			
	US 2002103234	A1	20020801	US 2001-910068	20010723	<--
	US 6630463	B2	20031007			
	US 2003144276	A1	20030731	US 2003-336756	20030106	<--
	US 6884808	B2	20050426			
PRAI	JP 1995-166004	A	19950630			
	JP 1996-141433	A	19960604			
	EP 1996-921104	A3	19960627			
	WO 1996-JP1782	W	19960627			
	US 1997-981770	A3	19971230			
	US 1999-313087	XX	19990517			
	US 2001-910068	A3	20010723			

OS MARPAT 126:186111
GI



I

AB Heterocyclic carboxylic acid derivs. AB(D)nCOM [A is a heteroaryl group which has at least one nitrogen atom and may be substituted, or the like; B is heteroarylene, CONH, CR6:CR7 (R6 and R7 being each H, lower alkyl or the like) or the like; D is arylene, heteroarylene or the like; n is 0 or 1; and M is hydroxyl, lower alkoxy or the like] are prepared In an in vitro retinoid receptor binding assay, tetrahydroquinoxaline derivative I showed IC50 of 1.6 nM, vs. IC50 of 1.1 nM shown by all-trans-retinoic acid.

IT **187402-24-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic carboxylic acid derivs. as retinoid receptor agonists)

RN 187402-24-0 CAPLUS

CN Benzamide, 4-[5-[1-(1,1-dimethylethyl)-5-(1-methylethyl)-1H-pyrazol-3-yl]-1H-pyrrol-2-yl]-N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 43 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:405020 CAPLUS

DN 125:87295

TI Functionalized polyimide-amides: molten state reaction mechanisms and kinetics

AU Grenier-Loustalot, Marie-Florence; Trillaud, Marc; Grenier, Philippe

CS Lab. Physicochimie Polymeres, CNRS-URA 1494, Pau, 64000, Fr.

SO High Performance Polymers (**1996**), 8(2), 185-223
CODEN: HPPOEX; ISSN: 0954-0083

PB Institute of Physics Publishing

DT Journal

LA English

AB Molten state polymerization mechanism and kinetics of telechelic bismaleimide-

and nadimide-functionalized polyimide-amides (PIA) were investigated by using model compds. characteristic of reactive chain ends, and the data obtained were applied to study industrial prepolymers, such as 1500 mol. weight prepolymers and preimpregnated carbon fibers. Model compds. were synthesized and studied between 100 and 300° by HPLC, 1H and 13C NMR (liquid and solid), FTIR and DSC. A number of precise parameters of reactions including isomerization, crosslinking, co-reactions and side reactions were determined

IT **178921-13-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(model compound for molten state reaction mechanisms and kinetics of bismaleimide- and nadimide-functionalized polyimide-amides)

RN 178921-13-6 CAPLUS

CN Benzamide, 4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-N-(4-methylphenyl)-(9CI) (CA INDEX NAME)



L5 ANSWER 44 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:391648 CAPLUS

DN 125:58522

TI Preparation of 3,5-diphenyl-1,2,4-triazole derivatives as insecticides and acaricides

IN Ozaki, Masami; Yumita, Takashi; Suzuki, Junko; Nakatani, Masahisa; Taketo, Nobuo; Yano, Juko; Asaoka, Mieko; Kurihara, Hiroshi; Hirano, Tadami

PA Kumiai Chemical Industry Co, Japan; Ihara Chemical Ind Co

SO Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08092224	A2	19960409	JP 1994-248813	19940916 <--
PRAI	JP 1994-248813		19940916		

OS MARPAT 125:58522

GI



I

Q= 



II

Q1= 

AB The title compds. [I; R1 = alkyl; R2 = halo, alkyl, alkoxy, alkylthio, NO2, cyano, haloalkyl; Y = halo, NO2, cyano, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy; m, n = 0, 1-5; when m or n ≥2, X or Y is same or a combination of different groups; A = (CH2)jZ2(CH2)k; wherein Z2 = NR3, CO, NR3CO, CONR3, O2CNR3, NR3CONR3, O2C, CO2, N:CH, CH:N, ON:CR3; R3 = H, alkyl, cycloalkyl; j, k = 0,1; R2 = H, alkyl, Q; wherein Z, Z1 = CH, N; R4 = halo, NO2, cyano, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkyl, haloalkoxy, haloalkylthio, haloalkylsulfinyl, haloalkylsulfonyl, alkylamino, dialkylamino; p = 0, 1-3; when p≥2, R4 is same or a combination of different groups] are prepared Thus, 5-(4-formamidophenyl)-1,2,4-triazole derivative (II; R = CHO) (preparation given)
1.39, Me3COK 0.6, and 2-methanesulfonyl-5-trifluoromethylpyridine 1.00 g were added to DMF and heated with stirring at 60-70° for 5 h to give the title compound II (R = Q1) (0.80 g). Cabbage leaves were dipped in a 500 ppm solution of the latter compound and air-dried and contacted with Plutella xylostella konaga larvae for 6 days to kill ≥90% of the insect.

IT **178204-24-5P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diphenyltriazole derivs. as insecticides and acaricides)

RN 178204-24-5 CAPLUS

CN Benzamide, 4-[3-(2-chloro-6-fluorophenyl)-1-methyl-1H-1,2,4-triazol-5-yl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 45 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:928197 CAPLUS
DN 123:340128
TI Preparation of N-aminoimidazolinones as agrochemical fungicides
IN Bascou, Jean-Philippe; Desbordes, Philippe; Gadras, Alain; Perez, Joseph; Emeric, Gilbert; Lacroix, Guy; Veyrat, Christine
PA Rhone-Poulenc Agrochimie, Fr.
SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 668270	A2	19950823	EP 1995-420037	19950216	<--
	EP 668270	A3	19951011			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
	FR 2716192	A1	19950818	FR 1994-2135	19940217	<--
	FR 2716192	B1	19960412			
	ZA 9501196	A	19960716	ZA 1995-1196	19950214	<--
	AU 9512245	A1	19950824	AU 1995-12245	19950215	<--
	BR 9500584	A	19951024	BR 1995-584	19950215	<--
	CA 2142647	AA	19950818	CA 1995-2142647	19950216	<--
	FI 9500710	A	19950818	FI 1995-710	19950216	<--
	HU 71916	A2	19960228	HU 1995-466	19950216	<--
	JP 07278117	A2	19951024	JP 1995-53462	19950217	<--
	CN 1111241	A	19951108	CN 1995-103234	19950217	<--
PRAI	FR 1994-2135	A	19940217			

OS MARPAT 123:340128
GI



I



III

AB Title compds. [I; R = (hetero)aryl, etc.; R1 = H, vinyl, allyl, (halo)alkyl, etc.; R2 = H when n = 0; R2 = (halo)alkyl, cyclopropyl when n = 1; R3 = (hetero)aryl; R4 = H, CHO, acyl, etc.; X = O, S, SO; Z = O or S; Z1 = (hetero)arylene; Z2 = O, CO, NH, etc.] were prepared Thus, 5-(4-benzyloxyphenyl)-5-methylhydantoin was hydrolized and the esterified alanine treated with CSCl2 to give PhZ2C6H4CMe(CO2Me)NCS (II; Z2 = O). II (Z2 = S) was cyclocondensed with PhNHNH2 and the product alkylated with MeI to give title compound III which gave ≥75% control of Puccinia recondita on wheat when sprayed at 1g/L.

IT **170440-53-6P 170440-54-7P 170440-56-9P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aminoimidazolinones as agrochem. fungicides)

RN 170440-53-6 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-4-[4,5-dihydro-4-methyl-2-(methylthio)-5-oxo-1-(phenylamino)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 170440-54-7 CAPLUS

CN Benzamide, 4-[4,5-dihydro-4-methyl-2-(methylthio)-5-oxo-1-(phenylamino)-1H-imidazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 170440-56-9 CAPLUS

CN Benzamide, N-(3-chlorophenyl)-4-[4,5-dihydro-4-methyl-2-(methylthio)-5-oxo-1-(phenylamino)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:792609 CAPLUS

DN 123:198780

TI Preparation of arthropodicidal oxazolines and thiazolines

IN Lahm, George Philip; Stevenson, Thomas Martin

PA du Pont de Nemours, E. I., and Co., USA

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9504726	A1	19950216	WO 1994-US7459	19940729	<--
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, US, UZ, VN					
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	AU 9475128	A1	19950228	AU 1994-75128	19940729	<--
	AU 675165	B2	19970123			
	EP 712394	A1	19960522	EP 1994-925087	19940729	<--
	EP 712394	B1	20011128			
	R: DE, ES, FR, GB, GR, IT, PT					
	CN 1131945	A	19960925	CN 1994-193495	19940729	<--
	BR 9407346	A	19961008	BR 1994-7346	19940729	<--
	JP 09501426	T2	19970210	JP 1995-506408	19940729	<--
	JP 3597194	B2	20041202			
	ES 2165395	T3	20020316	ES 1994-925087	19940729	<--
	PT 712394	T	20020328	PT 1994-925087	19940729	<--
	ZA 9405784	A	19960205	ZA 1994-5784	19940803	<--
	IN 177790	A	19970222	IN 1994-CA1032	19941212	<--
	US 5686393	A	19971111	US 1996-586797	19960201	<--
PRAI	US 1993-101212	A	19930804			
	US 1994-203060	A	19940228			
	WO 1994-US7459	W	19940729			

OS MARPAT 123:198780
GI



I



II

AB The title compds. [I; A = direct bond, C1-3 (un)branched alkylene; E = C1-4 alkyl or haloalkyl; R1, R2 = H, halogen, C1-6 alkyl or haloalkyl, alkylthio, CN, NO2; R3 = C3-7 haloalkyl, (un)substituted C2-10 haloalkenyl, etc.; R4, R5 = H, halogen, CN, NO2, C1-16 alkyl or alkoxy, haloalkyl, haloalkoxy, cycloalkyl, (un)substituted alkenyl, (un)substituted alkynyl; Z = O, S; q = 0-3], especially useful as nematocides, acaricides, etc., are prepared and I-containing formulations presented. Thus,

oxazoline II (oil) was prepared and demonstrated ≥80% mortality to Tetranychus urticae when applied in 7 50-ppm doses over the course of 7 days.

IT **167855-95-0P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arthropodicidal oxazolines and thiazolines)

RN 167855-95-0 CAPLUS

CN Benzamide, 4-[2-(2,6-difluorophenyl)-4,5-dihydro-4-oxazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 47 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:264625 CAPLUS

DN 122:56039

TI Substituted thiazole derivatives useful as platelet aggregation inhibitors

IN Sanfilippo, Pauline J.; Urbanski, Maud; Carson, John R.; Carmosin, Richard J.

PA McNeil-PPC, Inc., USA

SO U.S., 22 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5342851	A	19940830	US 1992-958193	19921007 <--
PRAI US 1992-958193		19921007		

OS MARPAT 122:56039

GI



I

AB This invention relates to substituted thiazole derivs. I [R and R3 are the same or different and are selected from H, OH, CO2H, C1-4-alkylcarboxy, C1-8-alkyl, CF3, halo, (un)substituted Ph, etc.; R1 is selected from H, halo, OH, CO2H, C1-4-alkylcarboxy, C1-5-alkyl, CF3, (un)substituted Ph; R2 = H, C1-5-alkyl; A is selected from carbonyl, carboxyl, carboxamido,

amido, oxymethyl, aminomethyl, methylene; B is selected from C1-9-alkyl, C1-9 branched alkyl, Ph, C1-5-aralkyl; Q is selected from OH, C1-5-alkoxy, halo, cyano, CO2H, C1-5-alkoxycarbonyl, NR4R5, where R4 and R5 are independently H, C1-5-alkyl, C3-8-cycloalkyl, or NR4R5 = heterocycle or guanidine, urea, thiourea, hydrazine, (un)substituted amidine]. These compds. are useful as inhibitors of platelet aggregation and inhibitors of adhesion mols. and may be provided in pharmaceutical compns. and in methods of treating reperfusion thrombosis injury in patients. ICx values (the concentration of the compound in μM at which the increase in light transmission = x% in drug-treated platelet concentrate vs. control) were as high as x = 90 at 20 μM. Formulations were given.

IT **159887-58-8P 159887-59-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted thiazole derivs. useful as platelet aggregation inhibitors)

RN 159887-58-8 CAPLUS
CN Benzamide, N-[4-(aminoiminomethyl)phenyl]-4-[2-(3-methoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 159887-59-9 CAPLUS
CN Benzamide, N-[4-(aminoiminomethyl)phenyl]-4-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 48 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:234791 CAPLUS
DN 122:9879
TI Preparation of pyridine compounds.
IN Mitchell, William Leonard; Clitherow, John Watson
PA Glaxo Group Ltd., UK
SO Brit. UK Pat. Appl., 54 pp.
CODEN: BAXXDU
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2276163	A1	19940921	GB 1993-5509	19930317 <--
PRAI	GB 1993-5509		19930317		

OS MARPAT 122:9879
GI



I



II

AB Title compds. I (R1 = H, halo, C1-6 alkyl, C1-6 alkoxy; R2, R3 = H, halo, C1-6 alkyl, HO-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy, HO, NC, O2N, R6O2C, R6CO, R6R7NCO, etc., wherein R6, R7 = H, C1-4 alkyl, R6R7N = 5-6-membered heterocyclyl; R4, R5 = H, halo, HO, C1-6 alkoxy, C1-6 alkyl; R8, R9 = R6; X = CONH, NHCO, CH2NH, NHCH2; p = 2-4) or a salt or solvate thereof, as 5-HT1D antagonists useful in treatment of CNS disorders, endocrine disorders and sexual dysfunction (no data), are prepared (E)-3-(2-cyanoethenyl)-4-methoxy-N-[4-(4-pyridinyl)phenyl]benzamide (preparation given) in DMF, EtOH and ethanolic dimethylamine was added to pre-reduced palladium oxide/C to give the title compound II.

IT **159533-48-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted arylpyridines as 5-HT1D antagonists)

RN 159533-48-9 CAPLUS
CN Benzamide, N-[3-[3-(dimethylamino)propyl]-4-methoxyphenyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 49 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:192334 CAPLUS

DN 120:192334
TI The structural isomer of 1,4-[bis(N-isoprenyl-N-benzoamido)]tetramethylbenzene and its polyimides via Diels-Alder reaction
AU Sun, F.; Wang, Y. T.; Ottenbrite, R. M.
CS Dep. Chem., Virginia Commonw. Univ., Richmond, VA, 23284, USA
SO Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (**1992**), 33(1), 1130-1
CODEN: ACPPAY; ISSN: 0032-3934
DT Journal
LA English
AB The copolymn. of 1,4-[bis(N-isoprenyl-N-(2,6-dimethyl)phenyl)]terephthalamide (I), prepared from N-isoprenyl-2,6-dimethylaniline and terephthaloyl chloride, was compared with that of its structural isomer 1,4-[bis(N-isoprenyl-N-benzoamido)]tetramethylbenzene (II). Diels-Alder copolymn. of I with different bismaleimides gave polyimides with a lower mol. weight than those obtained with II, due to the electron property difference between the 2 dienes. The polymers containing the benzoamido group in the backbone had better thermostability than the polymers prepared with II.
IT **154043-48-8P 154043-49-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties of)
RN 154043-48-8 CAPLUS
CN 1,4-Benzenedicarboxamide, N,N'-bis(2,6-dimethylphenyl)-N,N'-bis(2-methylene-3-butenyl)-, polymer with N,N'-[1,4-phenylenebis(oxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzamide] (9CI) (CA INDEX NAME)

CM 1

CRN 154043-47-7
CMF C40 H26 N4 O8

PAGE 1-A



PAGE 1-B



CM 2

CRN 154043-46-6
CMF C34 H36 N2 O2



RN 154043-49-9 CAPLUS
CN Benzamide, N,N'-[1,4-phenylenebis(oxy-4,1-phenylene)]bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with N,N'-(2,3,5,6-tetramethyl-1,4-phenylene)bis[N-(2-methylene-3-butenyl)benzamide] (9CI) (CA INDEX NAME)

CM 1

CRN 154043-47-7
CMF C40 H26 N4 O8

PAGE 1-A



PAGE 1-B



CM 2

CRN 124350-56-7
CMF C34 H36 N2 O2



L5 ANSWER 50 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:38915 CAPLUS
DN 118:38915
TI Preparation of 2-arylthiazole derivatives as pharmaceutical compositions
IN Kondo, Shiro; Fukushima, Hisashi; Hasegawa, Masaichi; Tsuchimoto, Masahiro; Nagata, Ikuo; Osada, Yoshio; Komoriya, Keiji; Yamaguchi, Hisao
PA Teijin Ltd., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9209279	A1	19920611	WO 1991-JP1670	19911129	<--
	W: AU, CA, HU, JP, KR, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, NL, SE					
	CA 2073981	AA	19920531	CA 1991-2073981	19911129	<--
	CA 2073981	C	20020108			
	AU 9189522	A1	19920625	AU 1991-89522	19911129	<--
	AU 645867	B2	19940127			
	EP 513379	A1	19921119	EP 1991-920699	19911129	<--
	EP 513379	B1	19960911			
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE					
	HU 63838	A2	19931028	HU 1992-2265	19911129	<--
	HU 218942	B	20010129			
	AT 142494	E	19960915	AT 1991-920699	19911129	<--
	ES 2092580	T3	19961201	ES 1991-920699	19911129	<--
	JP 2725886	B2	19980311	JP 1991-500083	19911129	<--
	SG 86971	A1	20020319	SG 1996-3299	19911129	<--
	US 5614520	A	19970325	US 1995-380214	19950130	<--
PRAI	JP 1990-330147	A	19901130			
	JP 1991-216586	A	19910802			
	WO 1991-JP1670	A	19911129			
	US 1992-917037	B1	19920730			

OS MARPAT 118:38915
GI



I

AB The title compds. [I; Ar = (un)substituted pyridyl, thienyl, furyl, naphthyl, (un)substituted Ph; X = H, alkyl, CO2H, alkoxycarbonyl, CONH2, alkylaminocarbonyl; Y = H, alkyl, OH, alkoxy, CO2H, alkoxycarbonyl, CONH2, mono- or dialkylaminocarbonyl], useful for treatment of gout, hyperuricemia and interleukin 1 production-related diseases, are prepared. Thus, 390 mg 3-isopropoxythiobenzamide and 360 mg ClCH2COCH2CO2Et were refluxed in EtOH for 5 h to give an ester as an oil which was saponified in 1N aqueous NaOH in EtOH to give 65% I [Ar = 3-iso-PrOC6H4, X = CO2H, Y = Me). I [Ar = 3,4-cyano(iso-BuO)C6H3, X = CO2H, Y = Me) at 1 mg/kg p.o. lowered 95% serum uric acid in mice. I also inhibited xanthine oxidase, production of interleukin 1, and collagen-induced inflammation. Tablets containing I [Ar = 3,4-O2N(iso-PrO)C6H3, X = CO2H, Y = Me] were prepared

IT **144059-96-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)

RN 144059-96-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[4-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:570914 CAPLUS

DN 117:170914

TI Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.

AU Makovec, Francesco; Peris, Walter; Revel, Laura; Giovanetti, Roberto; Redaelli, Daniele; Rovati, Lucio C.

CS Rotta Res. Lab., Monza, 20052, Italy

SO Journal of Medicinal Chemistry (**1992**), 35(20), 3633-40
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI



I

AB A series of new N-phenylbenzamido acid derivs. I [R1 = H, 4-Me, 4-Pr, 4-Bu, 4-HO, 3,4-(HO)2, 3,5-(HO)2, 4-MeO, 3,4-(MeO)2, 3,4,5-(MeO)3, 4-PrO, 3-Cl, 4-Cl, 2,4-Cl2, 4-CF3, 3-CN, 4-CN, 4-NO2, 4-CO2H, 4-(tetrazol-5-yl), R2 = 3,5-(CO2H)2; R1 = 4-CN, R2 = 3,4-, 2,4-, 2,3-, 2,5-(CO2H)2, 3-, 4-(tetrazol-5-yl), 3-CO2H-5-CH2OH, #-CO2H-5-CONH2; R1 = 4-(tetrazol-5-yl), R2 = H, 4-CN, 4-CONH2, 4-CO2H, 2-, 3-, 4-(tetrazol-5-yl), etc.] was synthesized and evaluated for their ability to inhibit the IgE-mediated passive cutaneous anaphylaxis in the rat (PCA), as well as for their capacity to inhibit gastric mucosal damage induced by the oral administration of absolute alc. in the rat. Some of these new derivs. exhibit potent antiallergic and cytoprotective activity, 20-80 times higher than that of the reference, disodium cromoglycate (DSCG). Structure-activity relationships are discussed. The antiallergic activity of one of the more potent compds. of this series, i.e. 4-(1H-tetrazol-5-yl)-N-[4-(1H-tetrazol-5-yl)phenyl]benzamide [I; R1 = R2 = 4-(tetrazol-5-yl); CR 2039] was further evaluated in vivo. This compound antagonizes the bronchoconstriction induced by aerosolized ovalbumin in both anesthetized and conscious IgE sensitized guinea pigs with ID50 of 3.7 mg/animal (tracheal insufflation) and 20 mg/kg (i.m.). Further cytoprotective effects were evaluated in gastric ulcer models induced by the acute oral administration of hypertonic sodium chloride solution or by acetic acid and by the subchronic administration of glucose in fasted animals. In the models used exptl. CR 2039 is effective, whereas DSCG seems to be devoid of any protective activity. Such a potent antiallergic and mucosal protectant could provide a new potential agent in the therapy of atopic allergic diseases.

IT **143330-27-2P 143330-28-3P 143330-29-4P 143330-31-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antiallergic and/or cytoprotective activity of)

RN 143330-27-2 CAPLUS
CN Benzamide, N-phenyl-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 143330-28-3 CAPLUS
CN Benzamide, N-(4-cyanophenyl)-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 143330-29-4 CAPLUS
CN Benzamide, N-[4-(aminocarbonyl)phenyl]-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 143330-31-8 CAPLUS
CN Benzoic acid, 4-[[4-(1H-tetrazol-5-yl)benzoyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 52 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:107296 CAPLUS
DN 116:107296
TI Synthesis and characterization of some imide endcapped amide-imides
AU Liu, F. J.; Munukutla, S.; Levon, K.; Tesoro, G.
CS Polytech. Univ., Brooklyn, NY, 11201, USA
SO Journal of Polymer Science, Part A: Polymer Chemistry (**1992**), 30(1), 157-62
CODEN: JPACEC; ISSN: 0887-624X
DT Journal
LA English
AB p-Maleimidobenzoyl chloride (I) and p-citraconimidobenzoyl chloride (II) are prepared, resp., from N-(p-carboxyphenyl)maleimide and N-(p-carboxyphenyl)citraconimide obtained by reacting p-aminobenzoic acid with, resp., maleic or citraconic anhydride. Reacting I or II with 1,4-phenylenediamine or 4,4'-methylenedianiline or 4-aminophenyl sulfone gives bismaleimide or biscitraconimide monomers. These monomers are polymerized to give polymers stable at ≤350°.
IT **99240-48-9P 139056-16-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and solubility and polymerization of)

RN 99240-48-9 CAPLUS

CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 139056-16-9 CAPLUS

CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

IT **99242-61-2P 139162-44-0P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation and thermal stability of)

RN 99242-61-2 CAPLUS

CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 99240-48-9

CMF C35 H24 N4 O6



RN 139162-44-0 CAPLUS
CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 139056-16-9
CMF C37 H28 N4 O6

PAGE 1-A



PAGE 1-B

L5 ANSWER 53 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:13235 CAPLUS
DN 116:13235
TI Silver halide photographic material with formalin resistance
IN Kaguchi, Hiroyuki; Hirabayashi, Shigeto
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03140949	A2	19910614	JP 1989-279255	19891026 <--

PRAI JP 1989-279255 19891026
GI



I

AB The photog. material having ≥1 light-sensitive Ag halide emulsion layers on a support contains a ballasted HCHO scavenger in ≥1 the layers. Thus, a multilayer color neg. film containing ballasted HCHO scavenger I in a protective layer showed HCHO resistance and no increase in brittleness.

IT **137994-92-4**
RL: USES (Uses)
(formalin coupler, for multicolor silver halide photog. emulsion)

RN 137994-92-4 CAPLUS

CN Benzamide, N-(4-decylphenyl)-4-(4,5-dihydro-5-imino-3-methyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 54 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:608721 CAPLUS
DN 115:208721
TI Synthesis of new bismaleimides and their copolymerization with bisdienes via Diels-Alder reaction
AU Sun, Fang; Wang, Yan Tong; Ottenbrite, Raphael M.
CS Dep. Chem., Virginia Commonw. Univ., Richmond, VA, 23284, USA
SO Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (**1991**), 32(1), 188-9
CODEN: ACPPAY; ISSN: 0032-3934
DT Journal
LA English
AB The title polyimides were prepared by the Diels-Alder copolymn. of bisdienes 1,4-[CH2:CHC(:CH2)CH2NR]2C6Me4 (R = H, Ac, Bz) and bismaleimides, e.g., [4-R1C6H4CONH]2X (R1 = maleimido, X = 1-C6H4CH2C6H4-4)].

IT **136837-55-3P 136837-56-4P 136837-57-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Diels-Alder polymerization)

RN 136837-55-3 CAPLUS

CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with 2,3,5,6-tetramethyl-N,N'-bis(2-methylene-3-butenyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 121135-58-8
CMF C20 H28 N2



CM 2

CRN 99240-48-9
CMF C35 H24 N4 O6



RN 136837-56-4 CAPLUS
CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with N,N'-(2,3,5,6-tetramethyl-1,4-phenylene)bis[N-(2-methylene-3-butenyl)acetamide] (9CI) (CA INDEX NAME)

CM 1

CRN 124350-53-4
CMF C24 H32 N2 O2



CM 2

CRN 99240-48-9
CMF C35 H24 N4 O6



RN 136837-57-5 CAPLUS
CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, polymer with N,N'-(2,3,5,6-tetramethyl-1,4-phenylene)bis[N-(2-methylene-3-butenyl)benzamide] (9CI) (CA INDEX NAME)

CM 1

CRN 124350-56-7
CMF C34 H36 N2 O2



CM 2

CRN 99240-48-9
CMF C35 H24 N4 O6



L5 ANSWER 55 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:553169 CAPLUS
DN 113:153169
TI Novel synthesis of aromatic polyamides by nickel-catalyzed polycondensation of aromatic dibromides, an aromatic diamine, and carbon monoxide
AU Yoneyama, Masaru; Konishi, Toru; Kakimoto, Masaaki; Imai, Yoshio
CS Dep. Org. Polym. Mater., Tokyo, Inst. Technol., Tokyo, 152, Japan
SO Makromolekulare Chemie, Rapid Communications (**1990**), 11(8), 381-6
CODEN: MCRCD4; ISSN: 0173-2803
DT Journal
LA English
AB Aromatic polyamides were prepared in the presence of Ni-containing catalysts [NiCl2, NiBr2, dichloro(2,2'-bipyridyl)nickel(II), and 2,2'-bipyridyl/NiCl2 complexes] by polymerization of bis(4-bromophenyl) ether (I) and bis(4-bromophenyl) ether, m-dibromobenzene (II), or 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene, with CO, using aprotic polar solvents and 1,8-diazabicyclo[5.4.0]-7-undecene as an HBr scavenger. Highest-viscosity (0.21 dL/g) I-II-CO copolymer was formed at 150°, while that prepared at 180° had viscosity 0.17 dL/g and no polymer was formed at 100°. No appreciable difference was in catalytic activity was observed with respect to the inherent viscosity of the resulting aramids. IR and NMR spectra confirmed formation of amide linkages.
IT **97429-39-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in presence of nickel catalysts)
RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 56 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:478399 CAPLUS
DN 113:78399
TI Preparation of 2,3,4-substituted imidazoles and 3,4,5-substituted 1,2,4-triazoles useful as antagonists of platelet activating factor (PAF)
IN Schromm, Kurt; Mentrup, Anton; Renth, Ernst Otto; Heuer, Hubert; Muacevic, Gojko; Birke, Franz
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.; Boehringer Ingelheim International G.m.b.H.
SO Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 335381	A1	19891004	EP 1989-105570	19890329 <--
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 3810848	A1	19891019	DE 1988-3810848	19880330 <--
	FI 8901449	A	19891001	FI 1989-1449	19890328 <--
	NO 8901293	A	19891002	NO 1989-1293	19890328 <--
	DD 283620	A5	19901017	DD 1989-326949	19890328 <--
	ZA 8902259	A	19901228	ZA 1989-2259	19890328 <--
	DK 8901514	A	19891001	DK 1989-1514	19890329 <--
	WO 8909212	A1	19891005	WO 1989-EP341	19890329 <--
	W: DE, HU, JP, KR, SU, US				
	FR 2629457	A1	19891006	FR 1989-4089	19890329 <--
	GB 2216890	A1	19891018	GB 1989-7042	19890329 <--
	HU 52091	A2	19900628	HU 1989-2149	19890329 <--
	JP 02503679	T2	19901101	JP 1989-503727	19890329 <--
	AU 8932286	A1	19891005	AU 1989-32286	19890330 <--
PRAI	DE 1988-3810848	A	19880330		
	WO 1989-EP341	W	19890329		

OS CASREACT 113:78399; MARPAT 113:78399
GI



I



II





III

IV

AB Title compds. I and II [XY = bond, CONR5, NR5CO, SO2NR5, NR5CONR5NR5, etc.; A = N, CH; B = 1- or 2-membered component of a mono- or polynuclear (hetero)aromatic ring system, especially CH:CH, S, O, NR5; Q, Q1, Q2, Q3 = bond, alkylene; plus Q = O, NR5; R1 = (un)substituted Ph, heterocyclyl; R2 = H, OH, acyloxy, (un)substituted aliphatic, etc.; R3 = (un)substituted carbo- or heterocyclyl; R4 = H, alkyl, alkoxy, halo; R5 = H, alkyl] were prepared as PAF antagonists, especially useful for treating inflammatory, allergic, or autoimmune diseases. Thus, cyclocondensation of Et acetate (methylthenoyl)hydrazonide III with p-amino-N-(3-pyridyl)benzamide at 170-190° gave triazole IV. The ethylthienyl analog of IV inhibited PAF-induced aggregation of thrombocytes with IC50 = 0.61 + 10-6 M.

IT **126768-25-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as PAF antagonist)

RN 126768-25-0 CAPLUS

CN Benzamide, N-(3-benzoylphenyl)-4-[3-(3,5-dimethoxyphenyl)-5-methyl-4H-1,2,4-triazol-4-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 57 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:458426 CAPLUS
DN 111:58426
TI Soluble high-temperature polymers containing a tetraphenylthiophene unit
AU Imai, Yoshio; Kakimoto, Masaaki
CS Dep. Org. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan
SO Polymer-Plastics Technology and Engineering (**1989**), 28(4), 371-414
CODEN: PPTEC7; ISSN: 0360-2559
DT Journal
LA English
AB The title polymers were prepared using 4 types tetraphenylthiophene monomers - diamine, diisocyanate, diacyl chloride, and dibromide. Aromatic polyimides and copolyimides were prepared by reaction of tetraphenylthiophenediamine (I) or tetraphenylthiophene diisocyanate (II) with tetracarboxylic dianhydrides or dithioanhydrides. Aromatic polyamides and copolyamides were obtained by reaction of I with diacyl chlorides or tetraphenylthiophenedicarboxylic acid chloride (III) with diamines. Aromatic polyamide-imides were prepared by reaction of I with 4-chloroformylphthalic anhydride and of II with trimellitic anhydride. The reaction of III with bisphenols and aminophenols gave aromatic polyesters and polyamide-esters, resp. Aromatic polyazomethines were prepared by reaction of I and aldehydes. All the polymers had high mol. weight, were soluble in organic solvents, and had glass transition temps. of .apprx.300°.
IT **97429-39-5P 97463-60-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solubility and glass transition temperature of)
RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

n

RN 97463-60-0 CAPLUS

CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 58 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:75489 CAPLUS
DN 110:75489
TI Preparation of N,1-diphenyl-2-pyrazoline-3-carboxamides as insecticides
IN Stevenson, Thomas Martin
PA du Pont de Nemours, E. I., and Co., USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8806583	A1	19880907	WO 1987-US3235	19871214 <--
	W: AU, BR, JP, KR				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8811544	A1	19880926	AU 1988-11544	19871214 <--
	AU 598633	B2	19900628		
	JP 01502513	T2	19890831	JP 1988-501073	19871214 <--
	JP 05081591	B4	19931115		
	EP 330678	A1	19890906	EP 1988-900910	19871214 <--
	EP 330678	B1	19901024		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	BR 8707672	A	19891003	BR 1987-7672	19871214 <--
	AT 57690	E	19901115	AT 1988-900910	19871214 <--
	ES 2008408	A6	19890716	ES 1988-6	19880104 <--
	CN 88100104	A	19880720	CN 1988-100104	19880105 <--
	ZA 8800040	A	19890927	ZA 1988-40	19880105 <--
PRAI	US 1987-326	A	19870105		

	US 1987-113530	A	19871028
	EP 1988-900910	A	19871214
	WO 1987-US3235	A	19871214

OS MARPAT 110:75489

GI



I



II



III

AB The title compds. [I; A = H, alkyl, (un)substituted Ph; B = H, alkenyl, alkynyl, alkoxycarbonyl, (un)substituted alkyl, Ph; X = O, S; X1, X2 = (un)substituted Ph; Y = H, alkyl, alkoxyalkyl, alkylthio, haloalkylthio, (un)substituted PhS] were prepared 4-ClC6H4NH2 was diazotized and the resulting solution added to MeCOCHClCO2Et in EtOH containing NaOAc to give, after 2 h stirring, 4-ClC6H4NHN:CClCO2Et which was refluxed with 4-ClC6H4CH:CH2 in benzene containing Et3N to give pyrazolinecarboxylate II (R = EtO). The latter was converted in 2 steps to II (R = Cl) which was stirred 18 h with 4-F3CC6H4NH2 to give II (R = 4-F3CC6H4NH), which gave ≥80% kill of fall armyworm larvae sprayed in cups at 0.5 lb./acre.

IT **118009-97-5P 118009-98-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide)

RN 118009-97-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4,5-dihydro-N,1-bis[4-(trifluoromethyl)phenyl]-5-[4-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 118009-98-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(4-chlorophenyl)-5-[4-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4,5-dihydro-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 59 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:31347 CAPLUS
DN 110:31347
TI Electrophotographic printing plate

IN Nishio, Yoshihiro; Nakamura, Masanobu; Fukawatase, Midori; Takahashi, Kenji
PA Dainippon Ink and Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63097965	A2	19880428	JP 1986-243769	19861014 <--
	JP 04042669	B4	19920714		
	US 4859555	A	19890822	US 1987-106843	19871013 <--
PRAI	JP 1986-243769	A	19861014		

OS MARPAT 110:31347
GI For diagram(s), see printed CA Issue.
AB The title printing plate has a light-sensitive layer containing a disazo compound, a perinone compound and a charge-transporting substance, dispersed in an alkali-soluble resin. The disazo compound is represented by I [X = H, CH3, OCH3, Cl, Br; Y = CONHC6H4NO2, CONHN:CHAr, CONHN:CR1R2, Q where Ar = (substituted phenyl, naphthyl, anthryl, pyridyl, thenyl, furyl, carbazolyl; R1, R2 = alkyl, aryl; A = (substituted) hydrocarbon or heterocyclic ring], II [Cp = aromatic coupler; B, D = H, halogen, lower alkyl, lower alkoxy], and III [X1, X2 = H, halogen, alkyl, alkoxy, nitro; Y1, Y2 = CONR3R4, CONHN:CR3R4 (R3, R4 = H, (substituted) hydrocarbon or heterocyclic ring; R1 and R2 may be bonded together to form a ring); Z and Z1 are the atoms necessary for forming a naphthalene or carbazole ring]. The perinone compound may be bisbenzimidazo[2,1-b:2',1'-i]benzo[1,m,n][3,8]phenanthroline-8,17-dione. The printing plate shows high sensitivity to a visible-light projection exposure. The printing plate is useful for a laser printing system.
IT **117311-69-0**
RL: USES (Uses)
(disazo compound, electrophotog. printing plate using)
RN 117311-69-0 CAPLUS
CN Benzamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis[azo(2-hydroxy-1,3-naphthalenediyl)-1,3,4-oxadiazole-5,2-diyl]]bis[N-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 60 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:23882 CAPLUS
DN 110:23882
TI Insecticidal pyrazolinecarboxanilidess, and their compositions and use in insect control
IN Stevenson, Thomas Martin

PA du Pont de Nemours, E. I., and Co., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8805046	A2	19880714	WO 1988-US1	19880104 <--
	WO 8805046	A3	19880811		
	W: SD, US, US				
	EP 330678	A1	19890906	EP 1988-900910	19871214 <--
	EP 330678	B1	19901024		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ES 2008408	A6	19890716	ES 1988-6	19880104 <--
	CN 88100104	A	19880720	CN 1988-100104	19880105 <--
	ZA 8800040	A	19890927	ZA 1988-40	19880105 <--
	US 5091405	A	19920225	US 1989-378529	19890512 <--
PRAI	US 1987-326	A1	19870105		
	US 1987-113530	A1	19871028		
	WO 1988-US1	W	19880104		

OS MARPAT 110:23882
GI



I II

AB The title compds. [I; R1 = substituted Ph; R2 = (un)substituted Ph; X = O, S; Y = H, alkyl, alkoxyalkyl, alkylthio, haloalkylthio, alkoxycarbonyl, CHO, alkanoyl, haloalkanoyl, (un)substituted PhS; A = H, alkyl, cyano, CO2R3, COR3, CONR3R4, CSNR3R4, C(S)R3, CS2R3, (un)substituted Ph; B = H, alkyl, haloalkyl, alkoxyalkyl, cyanoalkyl, alkoxycarbonylalkyl, alkenyl, alkynyl, alkoxycarbonyl, (un)substituted Ph, PhCH2; R3 = (halo)alkyl, (halo)alkenyl, (halo)alkynyl, alkoxyalkyl, alkylthioalkyl, nitroalkyl, cyanoalkyl, alkoxycarbonylalkyl, (halo)cycloalkyl, (un)substituted Ph, PhCH2; R4 = H, alkyl; R3R4 = (CH2)4, (CH2)5, CH2CH2OCH2CH2] are prepared as insecticides. Reaction of 4-ClC6H4NHN:CClCO2Et (preparation given) with 4-ClC6H4CH:CH2 via formation and dipolar cycloaddn. of a nitrile-imine (Et3N in C6H6) gave Et 1,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylate, which was saponified, converted to the acid chloride, amidated with 4-H2NC6H4CF3 to give pyrazolinecarboxanilide II. A formulation contained 10% II on attapulgite granules. As a spray at 0.55 kg/ha II gave ≥80% kill of Spodoptera frugiperda larvae.

IT **118009-97-5P 118009-98-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide)

RN 118009-97-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4,5-dihydro-N,1-bis[4-(trifluoromethyl)phenyl]-5-[4-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 118009-98-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(4-chlorophenyl)-5-[4-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4,5-dihydro-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 61 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:601378 CAPLUS
DN 109:201378
TI Electrophotographic material for printing plate preparation
IN Nishio, Yoshihiro; Nakamura, Masanobu; Fukawatase, Midori; Takahashi, Kenji
PA Dainippon Ink and Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63097966	A2	19880428	JP 1986-243770	19861014 <--
PRAI JP 1986-243770		19861014		

OS MARPAT 109:201378
GI For diagram(s), see printed CA Issue.
AB The title material has a light-sensitive layer containing a disazo compound, a condensed polycyclic quinone, and a charge-transporting substance which are dispersed in an alkali-soluble resin. The disazo compound may be I [X = H, CH3, OCH3, Cl, Br], II [Y = CONHN:CHAr, CONHN:CR1R2, Q (Ar = (substituted)phenyl, naphthyl, anthryl, pyridyl, thienyl, furyl, carbazolyl; R1, R2 = alkyl, aryl; A = (substituted) hydrocarbon or heterocyclic ring)], III [Cp = aromatic coupler; B, C = H, halogen, lower alkyl, lower alkoxy], IV [X1, X2 = H, halogen, alkyl, alkoxy, nitro; Y1, Y2 = CONR3R4, CONHN = CR3R4 (R3, R4 = H, (substituted) hydrocarbon on heterocyclic ring; R1 and R2 may be bonded together to form a ring)], or V. The material shows high sensitivity to visible-light projection exposure. The material is exposed using a laser printing system having a gas-laser or emission diode as the light source.
IT **117311-69-0**
RL: USES (Uses)
(electrophotog. material containing, for printing plate preparation)
RN 117311-69-0 CAPLUS
CN Benzamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis[azo(2-hydroxy-1,3-naphthalenediyl)-1,3,4-oxadiazole-5,2-diyl]]bis[N-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 62 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:576571 CAPLUS
DN 107:176571
TI Preparation of polyamides having 2-phenyl-4,5-imidazolediyl units in the main chain
AU Akutsu, Fumihiko; Kataoka, Toshiyuki; Naruchi, Kiyoshi; Miura, Masatoshi;

Nagakubo, Kuniharu
CS Fac. Eng., Chiba Univ., Chibashi, 260, Japan
SO Polymer (**1987**), 28(10), 1787-90
CODEN: POLMAG; ISSN: 0032-3861
DT Journal
LA English
AB Polyamides having 2-phenyl-4,5-imidazolediyl units in the main chain were prepared from 4,4'-(2-phenyl-4,5-imidazole)dibenzoic acid and aromatic diamines. Polycondensation by a direct solution method gave high-mol.-weight polymers. The polymers were highly soluble in polar solvents and had high glass temps. (>290°) and decompose temps. (>440°). Films were cast from AcNMe2 or 1-methyl-2-pyrrolidone solns. The tensile strength, elongation at break, and tensile modulus of the polymers were evaluated.
IT **110651-32-6P 110651-33-7P 110651-34-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties of)
RN 110651-32-6 CAPLUS
CN Poly[(2-phenyl-1H-imidazole-4,5-diyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 110651-33-7 CAPLUS
CN Poly[(2-phenyl-1H-imidazole-4,5-diyl)-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 110651-34-8 CAPLUS
CN Poly[(2-phenyl-1H-imidazole-4,5-diyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

n

IT **110906-01-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model compound for phenylimidazolediyl-containing polyamides)
RN 110906-01-9 CAPLUS
CN Benzamide, 4,4'-(2-phenyl-1H-imidazole-4,5-diyl)bis[N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 63 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:575939 CAPLUS
DN 107:175939
TI Imidazoles containing biologically active units. II. Synthesis of some 4-arylidene-2-aryl-5-oxo-4,5-dihydroimidazoles
AU El-Sharief, A. M. S.; Abd El-Maged, M. F.; Hammad, N. I. S.; Ammar, Y. A.; Harb, A. A.
CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt
SO Egyptian Journal of Chemistry (**1986**), Volume Date 1985, 28(1), 1-14
CODEN: EGJCA3; ISSN: 0367-0422
DT Journal
LA English
OS CASREACT 107:175939
GI



I

AB Title compds. I [Rn = halo, (NO2)2; R1 = H, Me, cyclohexyl, 4-HO2CC6H4, 4-HOC6H4, derivatized 4-carboxyphenyl or 4-hydroxyphenyl; R2 = H, Me, OMe] were prepared from the corresponding oxazolinones by treatment with NH4OAc in HOAc in the presence of fused NaOAc. They showed bactericidal activity.
IT **110816-13-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 110816-13-2 CAPLUS
CN Benzamide, 4-[2-(4-bromophenyl)-4,5-dihydro-4-[(4-methylphenyl)methylene]-5-oxo-1H-imidazol-1-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:626174 CAPLUS
DN 105:226174
TI β-Lactam derivatives, and compositions containing them
IN Taylor, Andrew William; Cook, Richard Thomas
PA Beecham Group PLC, UK
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8504878	A1	19851107	WO 1985-GB161	19850412 <--
	W: GB, JP, US				
	RW: CH, DE, FR, GB, IT, NL				
	EP 177596	A1	19860416	EP 1985-902070	19850412 <--
	R: CH, DE, FR, GB, IT, LI, NL				
PRAI	GB 1984-9986	A	19840417		

GI For diagram(s), see printed CA Issue.

AB β-Lactams I [R1 = (un)substituted Ph; OH, NH2, halo, or C1-6 alkoxy (un)substituted 5- or 6-membered heterocyclyl with 1-3 hetero atoms (O, S, or N); R2 = substituted NH2; R3 = H, C1-6 alkyl; R4 = H, Me, Ac, R5 = H, MeO, NHCHO; Y = SCMe2, SCH2, Y1CH2C(Z):; Y1 = O, S, CH2; Z = H, halo, organic group], useful as antibacterials, were prepared 2-p-Aminophenyl-4-ethoxycarbonyl-3-pyrazolin-5-one was saponified with boiling aqueous 0.5 N NaOH to give 97% of the acid which was refluxed with (Me3Si)2NH and the product acetylated in CH2Cl2 to give 67% 2-p-acetylaminophenyl-3-pyrazolin-5-one-4-carboxylic acid. This was converted to the acid chloride which reacted with ampicillin to give 6β-[D,2-(2-p-acetylaminophenyl-3-pyrazolini-5-one-4-carbonylamino)-2-phenyl]acetamidopenicillanic acid (II). II Na salt has a min. inhibitory concentration of 2.5 μg/mL against Escherichia coli NCTC 10418.

IT **105433-33-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with chloroformate)

RN 105433-33-8 CAPLUS
CN Benzeneacetic acid, 3,4-bis(acetyloxy)-α-[[[3-(acetyloxy)-1-[4-[(phenylamino)carbonyl]phenyl]-1H-pyrazol-4-yl]carbonyl]amino]-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 65 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:573279 CAPLUS
DN 105:173279
TI Polyamide resins
IN Imai, Yoshio; Kakimoto, Masaaki; Negi, Yuvraj Shingh
PA Tokyo Institute of Technology, Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61062523	A2	19860331	JP 1984-183831	19840904 <--
	JP 01049377	B4	19891024		
PRAI	JP 1984-183831		19840904		

AB Polyamides are prepared from derivs. of tetraphenylthiophene and diamines. The polyamides are soluble in organic solvents and have good heat resistance. Thus, a solution of 0.10 g 4,4'-oxydianiline in 1.5 mL AcNMe2 was cooled to 0°, treated with 0.257 g 2,5-bis[4-(chloroformyl)phenyl]-3,4-diphenylthiophene and 0.2 mL AcNMe2, and stirred in an ice bath for 1.5 h to give a polyamide (97% yield) which was soluble in N-methyl-2-pyrrolidone and AcNMe2, had intrinsic viscosity (0.5 g/dL in H2SO4 at 30°) 0.90, and had 10% weight loss at 520° in air or 515° in N.
IT **97429-39-5P 97463-60-0P**
RL: PREP (Preparation)
(preparation of soluble, heat-resistant)
RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 97463-60-0 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 66 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:534489 CAPLUS
DN 105:134489
TI Tetraphenylthiophenedicarboxylic acid derivatives

IN Imai, Yoshio; Kakimoto, Masaaki; Negi, Yuvraj Singh
PA Tokyo Institute of Technology, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61063672	A2	19860401	JP 1984-183832	19840904 <--
JP 01024151	B4	19890510		
PRAI JP 1984-183832		19840904		

AB Title compds. (acid, acid halide, or ester derivs.) useful as materials for heat resistant resins with excellent moldability, are prepared by treating tetraphenylthiophene (II) with carboxylic acid halides over Friedel-Crafts reagents. Thus, treating II with AcCl in nitrobenzene over AlCl3 at room temperature for 2 h with stirring gave 61% 2,5-bis(4-acetylphenyl)-3,4-diphenylthiophene, which was then heated with NaOCl at 70° for 18 h to give 94% tetraphenylthiophenedicarboxylic acid.

IT **97429-39-5P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of heat-resistant)

RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

n

L5 ANSWER 67 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:533757 CAPLUS
DN 105:133757
TI Dihydropyridinecarboxylate derivs.
IN Rosentreter, Ulrich; Perzborn, Elisabeth; Seuter, Friedel

PA Bayer A.-G. , Fed. Rep. Ger.
SO Ger. Offen., 41 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3431862	A1	19860313	DE 1984-3431862	19840830 <--
	US 4686229	A	19870811	US 1985-765908	19850814 <--
	EP 173204	A2	19860305	EP 1985-110353	19850819 <--
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	ES 546487	A1	19860716	ES 1985-546487	19850828 <--
	DK 8503934	A	19860301	DK 1985-3934	19850829 <--
	ZA 8506595	A	19860430	ZA 1985-6595	19850829 <--
	JP 61060683	A2	19860328	JP 1985-190018	19850830 <--
	ES 554062	A1	19870401	ES 1986-554062	19860416 <--
PRAI	DE 1984-3431862	A	19840830		

GI



I



AB The title compds. I [R1 = H, (un)substituted alkyl; R2 = H, alkyl; R3 = H, alkyl, CO2H, alkoxycarbonyl, (un)substituted aryl, CONHR4; R4 = Q (m = 0, 1), alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; n = 1-6; Z = S, O, NH] were prepared as antithrombotics. Thus, 4-(OCH)C6H4CHO was reduced with NaBH4 to give 34.5% 4-HOCH2C6H4CHO. This was cyclocondensed with NH3 and 3-(3-pyridyl)propyl acetoacetate to give 12% I [R1 = H, R2 = Me, R3 = 4-(HOCH2)C6H4, n = 3, Z = O] (II). In blood platelet prepns. II inhibited thromboxane A2 synthesis at 0.3-0.1 mg/L.

IT **104184-54-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antithrombotic)

RN 104184-54-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[4-[(phenylamino)carbonyl]phenyl]-, bis[3-(3-pyridinyl)propyl] ester (9CI) (CA INDEX NAME)



L5 ANSWER 68 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:616163 CAPLUS
DN 103:216163
TI Curing the bismaleimides: 3. Effect of structure on thermal behavior of bis(amide-maleimide)
AU Varma, Indra K.; Sharma, Shiromani
CS Cent. Mater. Sci. Technol., Indian Inst. Technol., New Delhi, 110016, India
SO Polymer (**1985**), 26(10), 1561-5
CODEN: POLMAG; ISSN: 0032-3861
DT Journal
LA English
AB The synthesis and characterization were described for six bismaleimide resins containing amide linkages in their backbones. The effect of structure on thermal behavior was investigated by introducing phosphine oxide, fluorene, ether, methylene, m-phenylene, and sulfone groups into the backbone. Thermal characterization of these bismaleimides was achieved using differential scanning calorimetry and thermogravimetric anal. The presence of an electron-withdrawing group in the backbone of the bisimide increased the curing temperature and reduced the reactivity of the maleimide bond. Thermal stability of the cured bismaleimide resins depended on their structure and the P- and fluorene-containing bisimide resins gave high char yields.
IT **99240-48-9P 99240-49-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 99240-48-9 CAPLUS
CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 99240-49-0 CAPLUS

CN Benzamide, N,N'-(oxydi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



IT **99242-61-2 99242-62-3**
RL: PRP (Properties)
(thermal properties of, structure effect on)

RN 99242-61-2 CAPLUS
CN Benzamide, N,N'-(methylenedi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 99240-48-9
CMF C35 H24 N4 O6



RN 99242-62-3 CAPLUS
CN Benzamide, N,N'-(oxydi-4,1-phenylene)bis[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 99240-49-0
CMF C34 H22 N4 O7



L5 ANSWER 69 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:454526 CAPLUS
DN 103:54526

TI Synthesis and characterization of soluble aromatic polyamides derived from 2,5-bis(4-chloroformylphenyl)-3,4-diphenylthiophene and aromatic diamines

AU Kakimoto, Masaaki; Negi, Yuvraj Singh; Imai, Yoshio
CS Dep. Text. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan

SO Journal of Polymer Science, Polymer Chemistry Edition (**1985**), 23(6), 1787-95
CODEN: JPLCAT; ISSN: 0449-296X
DT Journal
LA English

AB 2,5-Bis(4-carboxyphenyl)-3,4-diphenylthiophene [97483-30-2], was synthesized either by the Friedel-Crafts reaction of tetraphenylthiophene (I) [1884-68-0] with oxalyl chloride, or by the Friedel-Crafts acetylation of I followed by oxidation The low temperature solution polycondensation of 2,5-bis(4-chloroformylphenyl)-3,4-diphenylthiophene [97463-89-3] with various aromatic diamines in N,N-dimethylacetamide (II) afforded I-containing aromatic polyamides with inherent viscosities of 0.5-1.0 dL/g. Copolyamides were obtained from a mixture of the diacid chloride and isophthaloyl or terephthaloyl chloride. All except 2 of the polyamides were readily soluble in amide-type solvents including II and were cast into transparent and flexible films. These polymers had glass transition at .apprx.300°. Thermal stability of the polymers was evaluated by thermogravimetry, which showed no weight loss below 390° in both air and N atms.

IT **97429-39-5P 97463-60-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 97463-60-0 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-

phenylenemethylene-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 70 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:406820 CAPLUS
DN 103:6820
TI Preparation of polyamides containing α-diketone moieties and their transformation into 1,2,4-triazine rings with amidrazones
AU Akutsu, Fumihiko; Takeyama, Hidekazu; Miura, Masatoshi; Nagakubo, Kuniharu
CS Fac. Eng., Chiba Univ., Chiba, 260, Japan
SO Makromolekulare Chemie (**1985**), 186(3), 483-92
CODEN: MACEAK; ISSN: 0025-116X
DT Journal
LA English
AB Cyclization of aromatic diamine-4,4'-bis(chloroformyl)benzil copolymers with 4-chlorobenzamidrazone, 2-pyridinecarboxamidrazone, or acetamidrazone gave polyamides containing 1,2,4-triazine rings with conversions of 10-87%. The thermal stabilities and solubilities of these latter polymers were generally better than the α-diketone-containing polyamide starting materials. The triazine ring-containing polyamides were characterized by spectral and elemental anal. in relation to model compds.
IT **96817-74-2P 96817-75-3P 96817-76-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model for triazine ring-containing polyamides)
RN 96817-74-2 CAPLUS
CN Benzamide, 4,4'-[3-(4-chlorophenyl)-1,2,4-triazine-5,6-diyl]bis[N-phenyl- (9CI) (CA INDEX NAME)



RN 96817-75-3 CAPLUS
CN Benzamide, 4,4'-[3-(2-pyridinyl)-1,2,4-triazine-5,6-diyl]bis[N-phenyl- (9CI) (CA INDEX NAME)



RN 96817-76-4 CAPLUS
CN Benzamide, 4,4'-(3-methyl-1,2,4-triazine-5,6-diyl)bis[N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 71 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:123032 CAPLUS
DN 102:123032
TI Photographic elements for silver salt diffusion transfer
IN Endo, Katsusuke; Inagaki, Yoshio
PA Fuji Photo Film Co., Ltd. , Japan
SO Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 128594	A2	19841219	EP 1984-106828	19840614	<--
	EP 128594	A3	19850807			
	EP 128594	B1	19880107			
	R: DE, GB					
	JP 59231537	A2	19841226	JP 1983-106464	19830614	<--
	JP 05054103	B4	19930811			
	US 4520096	A	19850528	US 1984-620204	19840613	<--
PRAI	JP 1983-106464	A	19830614			

GI



AB A photog. image stabilizer for diffusion-transfer process comprises compound I or II (R = C1-14 alkyl; Z = C2-8 alkylene). Thus, a

polyethylene-laminated paper support was corona-charged, coated with a layer containing cellulose diacetate and Me vinyl ether-maleic acid anhydride copolymer, coated with a solution containing cellulose diacetate 20 g, Me2CO 200,
MeOH 20 mL, I (R = C6H13) 10-3 mol at 4 g/m2 of cellulose acetate; to this layer a solution containing cellulose diacetate 10 g, 1-phenyl-2-mercaptoimidazole 5 mg, Me2CO 200 mL was applied at 3 g/m3 of cellulose diacetate. To the above element was applied with an alkaline hydrolyzing solution containing Ag precipitants (prepared by adding a solution of Ni nitrate 0.7,
glycerin 100 g, H2O 7 mL to a solution containing Na sulfide 5 g, H2O 5 mL and mixing 40 g of it with a solution containing NaOH 55 g in H2O 300 and MeOH 1200 mL) at 30 mL/m2 to produce an image receiver. The photosensitive sheet containing Ag(Br,I) emulsion was imagewise exposed, contacted with the receiver and a processing composition was spread between them. After separation the
pos. image with Dmax 1.58 was obtained. The image was kept at 60° and 70% relative humidity for 72 h to show Dmax 1.45.

IT **95235-05-5**
RL: USES (Uses)
(photog. silver image stabilizer, for diffusion-transfer process, preparation of)

RN 95235-05-5 CAPLUS

CN Benzamide, 4-(2,3-dihydro-2-thioxo-1H-imidazol-1-yl)-N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 72 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1982:544886 CAPLUS
DN 97:144886
TI Heterocyclic compounds
IN Brown, David; Dowell, Robert Ian; Hargreaves, Rodney Brian; Main, Brian Geoffrey
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 61 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 52442	A1	19820526	EP 1981-305020	19811023 <--

EP 52442	B1	19850911			
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE					
ZA 8107597	A	19821027	ZA 1981-7597	19811103	<--
AU 8177091	A1	19820520	AU 1981-77091	19811104	<--
DK 8104988	A	19820515	DK 1981-4988	19811111	<--
FI 8103566	A	19820515	FI 1981-3566	19811111	<--
HU 26711	O	19830928	HU 1981-3367	19811111	<--
HU 185979	B	19850428			
NO 8103850	A	19820518	NO 1981-3850	19811113	<--
JP 57109771	A2	19820708	JP 1981-181250	19811113	<--
ES 507126	A1	19830701	ES 1981-507126	19811113	<--
CA 1176250	A1	19841016	CA 1981-390035	19811113	<--
DD 202020	A5	19830824	DD 1981-234877	19811116	<--
US 4423045	A	19831227	US 1981-321899	19811116	<--
ES 516588	A1	19831116	ES 1982-516588	19821016	<--
US 4503054	A	19850305	US 1983-528103	19830831	<--
US 4587246	A	19860506	US 1984-675741	19841128	<--
JP 62030771	A2	19870209	JP 1986-93476	19860424	<--
JP 62036370	A2	19870217	JP 1986-93477	19860424	<--
JP 05072384	B4	19931012			
US 4683232	A	19870728	US 1986-858126	19860501	<--
PRAI GB 1980-36680	A	19801114			
US 1981-321899	A3	19811116			
US 1983-528103	A3	19830831			
US 1984-675741	A3	19841128			

GI



I

AB Cardiotonic (no data) diazinones I [X = (un)substituted CH2, X1 = O, S, NR2; X = O, S, NH, X1 = CH2; R, R1 = H, cyano, NO2, amino, OH, alkylthio, (un)substituted alkoxy; R2 = H, alkyl] were prepared Thus 4-AcNHC6H4CHO was treated with S and piperidine to give 4-acetamidothiobenzoylpiperidine which was quaternized with BrCH2CO2H and treated with H2S to give 4-AcNHC6H4CS2CH2CO2H (II). II was treated with N2H4 to give 4-AcNHC6H4CSNHNH2 which was treated with BrCH2CO2H to give I (X = S, X1 = CH2, R = NHAc, R1 = H).

IT **83113-11-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 83113-11-5 CAPLUS

CN Benzamide, 4-(5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)-N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 73 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:58667 CAPLUS
DN 92:58667
TI Synthesis of 1-(p-carboxyphenyl)-3,5,5-trimethyl-2-pyrazoline. Its amides, esters, hydrazide, benzylidenes and thiosemicarbazide derivatives
AU Venkatesh, M. S.; Nadkarny, V. V.
CS Nadkarny-Sacasa Res. Lab., St. Xavier's Coll., Bombay, 400 001, India
SO Journal of the Indian Chemical Society (**1979**), 56(2), 216-18
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
OS CASREACT 92:58667
GI



I IV

AB Cyclization of Me2C:CHCOMe with p-HO2CC6H4NHNH2.HCl gave 69% I (R = OH), which was converted to the acid chloride and to 45-78% I [R = NHPh, p-XC6H4NH (X = Me, MeO, Br, Cl), 1- and 2-naphthyloxy, o- and p- O2NC6H4). I (R = OH) was converted to 70% hydrazide I (R = NHNH2; II) and then treated with aldehydes to give I (R = NHN:CHR1, R1 = MeOC6H4, p- and o-HOC6H4, 2-furyl, m-O2NC6H4). Reaction of II with R2NCS (R2 = Ph, p-tolyl, p-ClC6H4) gave 82-7% thiosemicarbazides I (R = NHNHCSNHR2; III). III were cyclized with NaOH to give 72-5% 3,4-disubstituted-5-mercaptotuazoles. The thiadiazoles IV were prepared similarly in 52-7% yield.
IT **71478-83-6P 71478-84-7P 71478-85-8P**
71478-86-9P 71478-87-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 71478-83-6 CAPLUS
CN Benzamide, 4-(4,5-dihydro-3,5,5-trimethyl-1H-pyrazol-1-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 71478-84-7 CAPLUS
CN Benzamide, 4-(4,5-dihydro-3,5,5-trimethyl-1H-pyrazol-1-yl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 71478-85-8 CAPLUS
CN Benzamide, 4-(4,5-dihydro-3,5,5-trimethyl-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 71478-86-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-4-(4,5-dihydro-3,5,5-trimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 71478-87-0 CAPLUS
CN Benzamide, N-(4-bromophenyl)-4-(4,5-dihydro-3,5,5-trimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 74 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:612556 CAPLUS
DN 91:212556
TI Anil synthesis. 20. Preparation of stilbenyl derivatives of 1,2,4-oxadiazoles
AU Berger, Hanny; Siegrist, Adolf Emil
CS Org.-Chem. Inst., Univ. Fribourg, Fribourg, CH-1705, Switz.
SO Helvetica Chimica Acta (**1979**), 62(5), 1411-28
CODEN: HCACAV; ISSN: 0018-019X
DT Journal
LA German
AB Schiff bases derived from 3- and 5-(p-formylphenyl)-1,2,4-oxadiazoles and chloroanilines react with various p-tolyl-substituted aromatic heterocycles in the presence of KOH and DMF to yield the corresponding substituted stilbenes, potentially useful as fluorescent whiteners. The reactivity of 5-[4-[[(4-chlorophenyl)imino]methyl]phenyl]-3-phenyl-1,2,4-oxadiazoles is very low, and side reactions predominate. Approx. 80 stilbene derivs. were prepared and their visible and fluorescence spectra tabulated.
IT **72094-44-1P 72094-50-9P**
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, as by-product of anil synthesis)
RN 72094-44-1 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-4-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)



RN 72094-50-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 75 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:204102 CAPLUS
DN 90:204102
TI 2-Substituted-5-hydroxy-1H-imidazole-4-carboxamide derivatives
IN Atsumi, Toshio; Tarumi, Yuzo; Yoshida, Noboru
PA Sumitomo Chemical Co., Ltd., Japan
SO Ger. Offen., 27 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2838892	A1	19790315	DE 1978-2838892	19780906 <--
	JP 54041874	A2	19790403	JP 1977-107641	19770906 <--
	JP 54059273	A2	19790512	JP 1977-124992	19771017 <--
	JP 54059284	A2	19790512	JP 1977-124995	19771017 <--
	JP 54122272	A2	19790921	JP 1978-28900	19780313 <--
	JP 61015873	B4	19860426		
PRAI	JP 1977-107641	A	19770906		
	JP 1977-124992	A	19771017		
	JP 1977-124995	A	19771017		
	JP 1978-28900	A	19780313		

GI



I

AB The imidazolecarboxamides I (R = C2-17 alkyl, C3-7 cycloalkyl, 1-adamantyl, pyridyl, pyridine N-oxide, Ph2CH, (un)substituted benzyl, (un)substituted Ph) were prepared Thus, PhCH2C(:NH)OEt was treated with H2NCH(CONH2)2 to give I (R = PhCH2). At 100 + 5 mg/kg/day I (R = Ph) inhibited Sorsoma 180 tumors in mice by 50.2%. The immunostimulant activity for several I was tabulated.

IT **70180-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 70180-76-6 CAPLUS
CN 1H-Imidazole-4-carboxamide, 5-hydroxy-2-[4-[(phenylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 76 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:144588 CAPLUS
DN 84:144588
TI Synthetic compounds related to cardenolides. VI. Pharmacological and biological study of the lactonic deoxybenzoin glucoside analogs
AU Prigent, Annie F.; Roche, Maurice; Pacheco, Henri
CS Serv. Chim. Biol., Inst. Natl. Sci. Appl., Villeurbanne, Fr.
SO European Journal of Medicinal Chemistry (**1975**), 10(5), 498-406
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA French
GI For diagram(s), see printed CA Issue.
AB The cardiotonic and Na-K-Mg dependent ATPase [9000-83-3] inhibiting activity of I [37636-71-8] and 11 derivs. was studied in isolated and homogenated frog, rat, dog, and rabbit hearts. Reduction of a carbonyl group decreased both the cardiotonic and ATPase inhibiting activity. Partial reduction of the ketone group decreased cardiotonic activity and eliminated ATPase inhibition. ATPase inhibition was conserved with total reduction of the ketone group without altering cardiotonic activity. Replacement of the methylene group with an amine did not alter the pharmacol. activity but did reduced the compound toxicity. The presence of amide(-NH-CO- or -CO-NH) linking the 2 phenyl groups eliminated all activity while the lengthening of this bridge by the addition of a methylene group caused only a decreased cardiotonic activity and eliminated all biochem. effects. Elimination of the phenyl group with the glucose side chain caused a marked increased in toxicity. The interat. distance between the lactone group and the hydroxyl group of the glycoside was the same as that observed in other digitalis glycosides. The presence of the of glycoside side chain, while not increasing the cardiotonic activity, caused a marked decrease in drug toxicity.
IT **58789-97-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cardiotonic activity of, ATPase in relation to)
RN 58789-97-2 CAPLUS
CN Benzamide, 4-(2,5-dihydro-5-oxo-3-furanyl)-N-[4-(β-D-glucopyranosyloxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 77 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1976:135997 CAPLUS
DN 84:135997
TI Synthetic compounds related to cardenolides. V. New amide analogs of lactonic deoxybenzoin glucosides
AU Prigent, Annie F.; Grouiller, Annie; Pacheco, Henri
CS Serv. Chim. Biol., Inst. Natl. Sci. Appl., Villeurbanne, Fr.
SO European Journal of Medicinal Chemistry (**1975**), 10(5), 490-7
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA French
GI



I



II

AB Glycosides I (X = CONH, NHCO, NHCOCH2) were prepared from II (R = NO2, NO2, CH2CO2H) resp. in multiple steps.
IT **58789-96-1P 58789-97-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58789-96-1 CAPLUS
CN Benzamide, 4-(2,5-dihydro-5-oxo-3-furanyl)-N-[4-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58789-97-2 CAPLUS
CN Benzamide, 4-(2,5-dihydro-5-oxo-3-furanyl)-N-[4-(β-D-glucopyranosyloxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 78 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1974:143985 CAPLUS
DN 80:143985
TI Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 leukemia cells
AU Sirotnak, Francis M.; Donsbach, Ruth C.
CS Mem. Sloan-Kettering Cancer Cent., New York, NY, USA
SO Cancer Research (**1974**), 34(2), 371-7
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English
AB The rate of influx, extent of concentrative uptake, and the rate of efflux (loss) by active transport in L1210 leukemia cells was compared for the pteridine antifolates, aminopterin and methotrexate, 8 related quinazoline

analogs, and 2 pyrimidine derivs. The data reveal a difference in the stereochem. specificity for influx and efflux. Influx was preferential in the order pteridine, quinazoline, and pyrimidine. Influx of aminopterin was more rapid than that of methotrexate. L-Glutamylquinazolines were taken up faster than L-aspartylquinazolines, but influx of a D-glutamylquinazoline was slower than the corresponding D-aspartyl derivative Influx of the quinazolines was faster when there was a methyl- or chloro-substitution at position 5. Influx of the pyrimidines was also faster when a methyl group was at position 6. Michaelis consts. (Km) for influx of the various analogs varied from 1.42 + 10-6M to over 10-4M. Individual Vmax values were essentially the same (1.87-2.22 nmoles/min/g dry weight). The relations between the values for initial velocity of influx (υ), the Km and Vmax obtained with each analog were in agreement with that predicted by the Michaelis-Menten equation and were consistent with the notion that differences in rates of influx are attributable to differences in the affinity of the carrier for the system. Efflux was preferential in the order pteridine, pyrimidine, and quinazoline. Efflux of aminopterin and methotrexate occurred at the same rate. Both aspartyl- and glutamylquinazolines efflux at about the same rate, but the D-aspartyl and D-glutamyl forms efflux more rapidly than the corresponding L forms. A methyl, and particularly a chloro, substitution at position 5 of the quinazoline reduces the rate of efflux. The extent of concentrative uptake observed for each analog directly reflects the relative magnitude at which the influx and efflux processes operate and may be the physiol. parameter most relevant to therapeutic efficacy.

IT **51741-95-8 51741-96-9**
RL: PROC (Process)
(transport of, by leukemia)

RN 51741-95-8 CAPLUS
CN L-Aspartic acid, N-[4-[[4-(2,4-diamino-5-pyrimidinyl)benzoyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51741-96-9 CAPLUS
CN L-Aspartic acid, N-[4-[[4-(2,4-diamino-6-methyl-5-pyrimidinyl)benzoyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 79 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1971:508293 CAPLUS
DN 75:108293
TI Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX
AU Kline, Ira; Gang, Miriam; Tyrer, Denis D.; Venditti, John M.; Artis, E. Waynn; Goldin, Abraham
CS Microbiol. Assoc., Inc., Bethesda, MD, USA
SO Cancer Chemotherapy Reports, Part 2 (**1971**), 2(1), 65-133
CODEN: CCSUBJ; ISSN: 0069-0120
DT Journal
LA English
AB Fifty-six compds. were tested against advanced systemic leukemia L1210 in mice, and the influence of the host, treatment schedule, and route and vehicle of drug administration on the antileukemic effectiveness of some of the most active compds. were studied. Of the alkylating agents tested, cyclophosphamide was the most active, although P,P-bis(1-aziridinyl)-N,N-diethylphosphinic amide was 45% as effective as methotrexate. Of the phthalanilides, 4',4"-bis[(3-methoxypropyl)amidino]terephthalanilide dihydrochloride was 58% as effective as methotrexate, and the activity of 4'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-4-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)benzamido]benzamilide dihydrochloride approximated that of methotrexate. 1,3-Bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-1-nitrosourea were 5- and 2-fold more active than methotrexate, resp. Cytosine arabinoside was the most effective pyrimidine, and actinobolin was the most active antibiotic tested. Purines and semicarbazones were relatively ineffective. Cyclophosphamide was equally effective when given s.c., i.p., or orally, over a wide range of treatment schedules. A 1:1 combination of N,N-bis(2-chloroethyl)phosphorodiamidic acid and cyclohexylamine was active when given s.c. or i.p., but not orally. Me sulfoxide as a vehicle for administration decreased the effectiveness of methotrexate, cyclophosphamide, methyl 1,1'-[(methylethanediylidene)dinitrilo]diguanidine dihydrochloride monohydrate, and 6-mercaptopurine; it also increased the toxicity of the latter 2 compds. There were no clearly defined differences in the response of hybrid and inbred leukemic mice to methotrexate, whereas 1,3-bis(2-chloroethyl)-1-nitrosourea was more effective against advanced leukemia in CDBA than in DBA/2 leukemic mice.
IT **4553-87-1**
RL: BIOL (Biological study)

(leukemia inhibition by)
RN 4553-87-1 CAPLUS
CN N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 80 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1971:77002 CAPLUS
DN 74:77002
TI Imido-substituted polyamides for coatings, moldings, and electrical insulation
IN Holub, Fred F.; Evans, Milton Lee
PA General Electric Co.
SO Ger. Offen., 23 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 2031574		19710107			<--
	CA 987327			CA		
	FR 2054013			FR		
	US 3689464		19720000	US		<--
	US 3763273		19730000	US		<--
	ZA 7003406		19700000	ZA		<--
PRAI	US		19690701			

GI For diagram(s), see printed CA Issue.
AB Polyamides, especially those based on 4,4'methylenedianiline, are substituted with imido groups such as those based on maleimido groups. Thus, 5.2 parts compound of formula I (R = NH2) was added to 1.96 parts maleic anhydride and 30 parts DMF at -20°, warmed to room temperature, treated with 1 part molten anhydrous NaOAc and 10 parts Ac2O, stirred 12 hr, poured into H2O, and the product I (R = maleimido) (II) isolated and dried. A film was cast from a solution of II in N-methylpyrrolidone containing 4% weight dicumyl peroxide, and was hardened 30 min at 150° and 30 min at 200°, giving a product that did not melt at 300° and was insol. and did not swell in N-methylpyrrolidone. The cut-through temperature of the film with a 50-mil wire was 330°. These products are useful in coatings of various types, moldings, and in elec. insulation.
IT **31851-16-8P**
RL: PREP (Preparation)
(preparation of)
RN 31851-16-8 CAPLUS

CN Nonanedi-p-toluidide, α,α'-bis[p-(p-maleimidobenzamido)phenyl]-, polymers (8CI) (CA INDEX NAME)

CM 1

CRN 47914-63-6
CMF C57 H50 N6 O8

PAGE 1-A



PAGE 1-B



L5 ANSWER 81 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1970:478557 CAPLUS
DN 73:78557
TI Bis[1,4]benzothiazino[3,2-b:2',3'-d]pyrroles as pigments for polymers
PA Badische Anilin- & Soda-Fabrik AG
SO Fr. Demande, 18 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2005669	A1	19691212	FR 1969-10550	19690404 <--
PRAI DE 1967-1769114	A	19680405		

GI For diagram(s), see printed CA Issue.

AB N-Aryldichloromaleimides are prepared and treated with 2-H2NC6H4SH derivs. or with 1,2-HSC10H6NH2 to give bis[1,4]benzothiazino[3,2-b:2',3'-d]pyrroles (I), orange to brown pigments for polymeric fibers. Thus, 1 equivalent p-H2NC6H4CONHPh was heated with 166 parts dichloromaleic anhydride in 1400 parts AcOH at 60° for 1 hr and at 110° for 4 hr to give 85% II. Similarly were prepared 33 addnl. N-aryldichloromaleimides and 15 N,N'-arylenebis(dicloromaleimides) in 30-95% yield. II was treated with o-H2NC6H4SH at 40° for 1 hr, at 80° for 1 hr,

and at 110° for 6 hr in AcOH to give 75% orange-red I (R = 4-C6H4CONHPh, X = Y = Z = H). Similarly were prepared 67 addnl. analogous pigments. The pigments were combined with linseed oil to form printing pastes and formed into coatings and lacquers with nitrocellulose, acrylate resins, melamine resins, or urea CH2O resins.

IT **29236-01-9P 29236-02-0P 29302-12-3P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 29236-01-9 CAPLUS
CN Benzanilide, 4'-chloro-4-(dichloromaleimido)- (8CI) (CA INDEX NAME)



RN 29236-02-0 CAPLUS
CN p-Benzanisidide, 4-(dichloromaleimido)- (8CI) (CA INDEX NAME)



RN 29302-12-3 CAPLUS
CN Benzanilide, 4-(dichloromaleimido)- (8CI) (CA INDEX NAME)



L5 ANSWER 82 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1968:402956 CAPLUS
DN 69:2956
TI Benzamidobenzanilide derivatives
IN Hirt, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 5 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 419145		19670228	CH	19640129 <--

GI For diagram(s), see printed CA Issue.

AB Mono- or dinitriles were treated with H2S or HCl-EtOH and a diamine to give the title products. Thus, p-aminobenzonitrile was treated with p-nitrobenzoyl chloride to give 4-nitro-4'-cyanobenzanilide, which was hydrogenated catalytically to give 4-amino-4'-cyanobenzanilide, which was treated with p-cyanobenzoyl chloride to give 4'-cyano-4-(p-cyanobenzamido)benzanilide (I). I (110 g.) suspended in 110 ml. piperidine and 330 ml. Me2NCHO was treated with H2S at 50° with cooling for 1 hr. and the mixture kept overnight to give 123 g. 4'-thiocarbamoyl-4-(p-thiocarbamoylbenzamido)-benzanilide (II), m. 328° (decomposition). 1,3-Diaminopropane (300 g.) was added to II while heating on a water bath for 3 hrs. and 300 ml. MeOH was added. The mixture was refluxed 1 hr., 2 1. H2O added, the precipitate filtered off, and washed with H2O and MeOH. The precipitate was suspended in 2 1. H2O and 150 g. lactic acid. The mixture was boiled to precipitate S, filtered with C, and boiled to remove H2S. The solution was filtered and 200 g. NaCl and 500 ml. H2O added to give a precipitate which was filtered off and washed with H2O and MeOH, and dried in vacuo. The product was dissolved in 80% HCO2H at 70°, filtered, and treated with 400 ml. absolute EtOH and 100 ml. EtOH-HCl at 60° to give a precipitate which was allowed to stand overnight to give 123 g. 4'-(1, 4, 5, 6-tetrahydro-2-pyrimidinyl)- 4 -[p-(1, 4, 5, 6-tetrahydro-2-pyrimidinyl)-benzamido]benzanilide (IIa)-di-HCl. II (8.0 g.) was treated similarly with 30 g. H2NCH2CH2NH2 on a steam bath 3 hrs. The mixture was treated with MeOH to give a precipitate which was filtered off, dissolved in propionic acid-H2O by heating, and treated with C and filtered. The filtrate was added to a NaCl solution to precipitate 8.8 g. 4'-(2-imidazolin-2-yl)-4 -[p-(2-imidazolin-2-yl)benzamido]benzanilide-di-HCl. II (10 g.) treated analogously with 20 g. 1,2-diaminopropane gave 6 g. 4'[4(or 5)-methyl-2-imidazolin-2-yl]-4-[p[4(or 5)-methyl-2-imidazolin-2-yl]benzamido]benzanilide-di-HCl, m. 255° (decomposition). p-Aminobenzonitrile was condensed with m-nitrobenzoyl chloride to give 3-nitro-4'-cyanobenzanilide which was hydrogenated catalytically to 3-amino-4'-cyanobenzanilide and treated with p-cyanobenzoyl chloride to give 4'-cyano-3-(p-cyanobenzamido)benzanilide (III), m. 285°. III (35 g.) was treated in 40 ml. piperidine and 120 ml. Me2NCHO with H2S 0.5 hr. to give 41 g. 4'-thiocarbamoyl-3-(p-thiocarbamoylbenzamido)benzanilide (IV), m. 240° (decomposition). IV (11 g.) was treated with 11 g. 1,2-diaminopropane to give analogously 13 g. 4'-[4-(or 5)-methyl-2-imidazolin-2-yl]-3-[o-[4(or 5)-methyl-2-imidazolin-2-yl]benzamido]benzanilide-di-HCl, m. 255-65° (decomposition). III (15 g.) was treated with 30 ml. 1, 3-diaminopropane to give analogously 19 g. 4'-(1, 4, 5, 6-tetrahydro-2-pyrimidinyl)- 3 -[p-(1, 4, 5, 6-tetrahydro-2-pyrimidinyl)-benzamido]benzanilide-di-HCl, m. 295° (decomposition). IV (6 g.) treated similarly with 25 g. H2NCH2CH2NH2 4 hrs. on a water bath give 4'- (2-imidazolin-2-yl)- 3 -[p-(2-imidazolin-2-yl)benzamido] benzanilide-di-HCl, m. 275° (decomposition). m-Aminobenzonitrile was condensed with p-nitrobenzoyl chloride to give 4-amino-3'-cyanobenzanilide, which was hydrogenated catalytically to give 4-amino-3'-cyanobenzanilide, which was treated with p-cyanobenzoyl chloride to give 3'-cyano-4-(p-cyanobenzamido)benzanilide (V), m. 265-72°. V (5 g.) was treated with H2S in 10 ml. piperidine and 30 ml. Me2NCHO to give 5.7 g. 3'-thiocarbamoyl-4-(p-thiocarbamoylbenzamido)benzanilide (VI), m. 265° (decomposition). VI (5.7 g.) was heated with 20 ml. (CH2NH2)2 to give 3'-(2-imidazolin-2-yl)-

4 -[p-(2-imidazolin-2-yl)benzamido]-benzanilide-di-HCl, m. 292° (decomposition). p-Aminophenylimidazoline was condensed with p-nitrobenzoyl chloride to give 4-nitro-4'-imidazolin-2-ylbenzanilide, which was hydrogenated catalytically to give 4-amino-4'-imidazolin-2-ylbenzanilide and treated with 4-cyanobenzoyl chloride to give 4-(2-imidazolin-2-yl)-4-(p-cyanobenzamido)benzanilide (VII). VII (16 g.) was treated 1 hr. on a water bath with H2S in 100 ml. Me2NCHO and 10 g. piperidine to give 11 g. 4'-(2-imidazolin-2-yl)-4-(p-thiocarbamoylbenzamido)benzanilide, which (10 g.) treated with 15 g. (CH2NH2)2 gave analogously IIb. These products are remedies against leukemia and cancer.

IT **4553-87-1P 13551-99-0P 13552-00-6P 13552-01-7P 13552-02-8P 13608-72-5P 13608-73-6P 19211-21-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 4553-87-1 CAPLUS
CN N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



●2 HCl

RN 13551-99-0 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-00-6 CAPLUS
CN N,4'-Bibenzamide, 4-(4-methyl-2-imidazolin-2-yl)-N'-[p-(4-methyl-2-imidazolin-2-yl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-01-7 CAPLUS
CN N,3'-Bibenzamide, 4-(4-methyl-2-imidazolin-2-yl)-N'-[p-(4-methyl-2-imidazolin-2-yl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-02-8 CAPLUS
CN N,3'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13608-72-5 CAPLUS
CN N,3'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13608-73-6 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(m-2-imidazolin-2-ylphenyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 19211-21-3 CAPLUS
CN N,4'-Bibenzamide, N'-(p-2-imidazolin-2-ylphenyl)-4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 83 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1967:116706 CAPLUS
DN 66:116706
TI 4-Benzoxazolyl-4'-oxadiazolylstilbenes
PA CIBA Ltd.
SO Neth. Appl., 63 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI NL 6611891		19660315			<--
PRAI CH		19640914			

GI For diagram(s), see printed CA Issue.
AB Compds. of the general formula I, suitable as heat-, light-, and migration-resistant fluorescent brightening agents, are prepared either by cyclizing benzoxazolyl-stilbene diacyl hydrazides, or by condensing an oxadiazolylstilbenecarboxylic acid with an o-aminophenol. Thus, a mixture of 7.2 g. 4-(2-benzoxazolyl)stilbene-4'-carboxylic acid chloride and 2.72 g. BzNHNH2 in 100 ml. pyridine is agitated successively at 0°, at room temperature, and for 1 hr. at 90-5°, cooled, poured into 1500 ml.

H2O, filtered, washed with H2O, and dried to give 8.4 g. of the diacyl hydrazide (II). A mixture of 9.18 g. II and 150 ml. SOCl2 is refluxed for 24 hrs., excess SOCl2 is distilled, and the residue washed with H2O and with MeOH, and dried to give 8.4 g. I (R = H, R1 = Ph), m. 287-8° (o-C6H4Cl2). Similarly prepared are the following I (R, R1, and m.p. given): H, 4-C6H4Ph, 305-6°; H, 4-C6H4CMe3, 290-1°; H, 4-C6H4CO2Me, 300°; H, 4-C6H4Me, 296-7°; H, 4-C6H4Cl, 317.5-18.5°; H, 4-C6H4CO2CHMe2, 300°; 5-Me, 4-C6H4O(CH2)7Me, 293-5°; 5-Me, 4-C6H4Me, 308-10°; 5-Me, Ph, 288-90°; 5-Me, 4-C6H4Ph, 323-5°; 5-Me, 4-C6H4CN, 319-21°; 5-Me, 3,5-C6H3Me2, 258-9° (PhCl); 5-Me, 2,4,6-C6H2Me3, 247-8° (HCONMe2); 5-Me, 3-C6H4CO2CHMe2, 285° (PhCl); 5-Me, 4-C6H4CH:CHPh, 340°; 5-Me, 3-pyridyl, 278-80°; 5-Me, 2-furoyl, 281-3°; 5-Me, 5-phenyl-2-thienyl, 341-3°; 5-Me, 5-methoxycarboxy-2-thienyl, 300°; 5-Me, 2-C10H7, 278-80° (HCONMe2); 5-Me, CH:CHPh, 295-7°; 5-Me3C, 4-C6H4Ph, 318-20° (PhCl-iso-PrOH); 5-Me3C, 4-C6H4OMe, 293-4° (PhMe); 5-Me3C, Ph, 262-3° (AcOEt); 5-Me3C, 4-C6H4CMe3, 280-2° (PhMe-iso-PrOH); 5-Ph, 4-C6H4CMe3, 320-2° (C6H4Me2); 5-Ph, Ph, 276-9°; 6-Ph, 4-C6H4CMe3, 293-5° (HCONMe2). A mixture of 6.6 g. 4-[5-(4-tert-butylphenyl)-2-oxadiazolyl]stilbene-4'-carboxylic acid chloride and 3 g. 3,4-H2N(HO)C6H3CH2Ph in 20 ml. C6H4Cl2 is refluxed until cessation of HCl evolution, treated with 15 ml. (BuOCH2CH2)2O and 300 mg. B2O3, and evaporated in a stream of N until the temperature reaches 230-5°, agitated for 30 min., cooled, dissolved in boiling xylene, clarified, concentrated, cooled, filtered, and washed with alc. to give 5.5 g. I (R = 5-PhCR2, R1 = 4-C6H4CMe3), lemon yellow blades, m. 281-2° (C6H4Me2). Similarly the following I (R1 = 4-C6H4CMe3) are prepared (R and m.p. given): 5-PhCMe2, 252-3° (PhMe); 5-Pr, 273-5° (PhMe); 5-C12H25, 188-90° (EtOAc); 5-Ph, 290-2°; 4,5,7-Me(Me3C)2, 245-6° (cyclohexane); 5-NCC2H4, 313-15°; 5-MeO2CC2H4, 272-4° (PhMe); 5-MeO2C, 323-5° (PhCl); 5-EtO2C, 298-300°; 5,7-(MeO2C)MeO, 232-4° (PhMe). Similarly other I (R = H, R1 = 4-C6H4COR3) are prepared (R3 and m.p. given): OH, >250° (HCONMe2); Cl, 350° (decomposition); O(CH2)17Me, 268-70° (C6H4Cl2); O(CH2CH2O)2Bu, 265-6° (PhCl); OCH2CH:CH2, 320° (C6H4Cl2); OCH2Ph, 302-4° (C6H4Cl2); 4-OC6H4CMe3, 354-6° (C6H4Me2); NHCH2CH2Ph, 316-18° (C6H4Cl2); NH(CH2)7Me, >320° (decomposition) (C6H4Cl2); NHCH2CH:CH2, 320° (C6H4Cl2) (decomposition); NHCH2CH(OH)Me, 305° (C6H4Cl2) (decomposition); morpholino, 288-90° (C6H4Cl2); 4-NHC6H4OMe, >350° (C6H3Cl3). Also prepared are the following I (R = 5-COR4, R1 = 4-C6H4CMe3) (R4 and m.p. given): OH, >350° (HCONMe2); Cl, 282° (decomposition); NHCH2CH:CH2, 300° (decomposition) (PhCl); NH(CH2)7Me, 300-3° (PhCl); NHCH2CH2Ph, 314-15° (C6H4Cl2); morpholino, 299-300° (decomposition) (PhCl); OC18H37, 250-5° (PhCl); OCH2CH:CH2, 289-91° (PhCl); OCH2Ph, 272-3° (PhCl); 4-OC6H4CMe3, 324-6° (PhCl); (OCH2CH2)2OBu, 247-50° (PhCl). Also prepared were III, m. 253-5° (C6H4Me2), and IV, m. >350° (C6H3Cl3).

IT **14944-94-6P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 14944-94-6 CAPLUS

CN p-Benzanisidide, 4-[5-[p-(p-2-benzoxazolylstyryl)phenyl]-1,3,4-oxadiazol-2-yl]- (8CI) (CA INDEX NAME)



L5 ANSWER 84 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1967:37925 CAPLUS
DN 66:37925
TI Benzamidobenzanilides
PA Dr. A. Wander, A.-G.
SO Brit., 7 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	GB 1047245		19661102	GB		<--
	CH 417604			CH		
	DE 1470421			DE		
	FR 3656			FR		
	US 3309367		19670000	US		<--
PRAI	CH		19630215			

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) inhibit bacterial and protozoal growth, especially Mycobacterium tuberculosis and trypanosomes, and are suitable for treatment of cancers, e.g. leukemia. They are prepared by condensation of an amine (II) with an acid (III) or an amine (IV) with an acid (V) in the presence of a condensin agent such as a carbodiimide. Alternatively, derivs. of III and V, such as anhydrides, may be used. IV are obtained by condensation of II with a nitrobenzoyl chloride followed by reduction to IV. Thus, N-nitro-4'-cyanobenzanilide, obtained by condensation of II (R1 = p-CN) with p-nitrobenzoyl chloride was catalytically hydrogenated to IV (R1 = p-CN) and condensed with p-cyanobenzoyl chloride to give I (R1 = R2 = p-CN), m. 320-5°. Through a mixture of 110 g. of this compound in 110 ml. piperidine and 330 ml. HCONMe2 at 50° was passed H2S 1 hr. to yield 123 g. I (R1 = R2 = C(S)NH2), m. 328° (decomposition); 106 g. of this dithioamide was added to 300 g. H2N(CH2)3NH2. After heating 3

hrs. on a water bath, 300 ml. MeOH was added, the mixture boiled 1 hr., 2 l. H2O added, and the mixture filtered. The precipitate was suspended in 2 l.H2O and
150 g. lactic acid, boiled, and filtered and to the filtrate was added 200 g. NaCl in 500 ml. H2O. The precipitate was treated with alc. HCl to give 123 g.
I (R1 = R2 = p-1,4,5,6-tetrahydro-2-pyrimidinyl)-2HCl, turns brown at 400°. Also prepared were the following HCl salts of I (attachment of amide bonds on central aryl nucleus, R1, R2, and m.p. given): p, p-2-imidazolin-2-yl, p-2-imidazolin-2-yl, turns brown 380°; p, p-Me, p-Me, 355° (decomposition); m, p-methyl-2-imidazolin-2-yl, p-1,4,5,6-tetrahydro-2-pyrimidinyl, 295° (decomposition); m, p-2-imidazolin-2-yl, p-2-imidazolin-2-yl, 275° (decomposition); p, p-2-imidazolin-2-yl, m-2-imidazolin-2-yl, 292° (decomposition).

IT **553-38-8P 4553-87-1P 4675-50-7P 13202-03-4P 13551-99-0P 13552-00-6P 13552-01-7P 13552-02-8P 13608-65-6P 13608-66-7P 13608-67-8P 13608-68-9P 13608-72-5P 13608-73-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 553-38-8 CAPLUS
CN Benzamide, 4-[[4-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)benzoyl]amino]-N-[4-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 4553-87-1 CAPLUS
CN N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



●2 HCl

RN 4675-50-7 CAPLUS
CN Benzamide, 4-[[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)benzoyl]amino]-N-[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 13202-03-4 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)-(8CI) (CA INDEX NAME)



RN 13551-99-0 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-00-6 CAPLUS
CN N,4'-Bibenzamide, 4-(4-methyl-2-imidazolin-2-yl)-N'-[p-(4-methyl-2-imidazolin-2-yl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-01-7 CAPLUS
CN N,3'-Bibenzamide, 4-(4-methyl-2-imidazolin-2-yl)-N'-[p-(4-methyl-2-imidazolin-2-yl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13552-02-8 CAPLUS
CN N,3'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13608-65-6 CAPLUS
CN N,3'-Bibenzamide, 4-(4-methyl-2-imidazolin-2-yl)-N'-[p-(4-methyl-2-imidazolin-2-yl)phenyl]- (8CI) (CA INDEX NAME)



RN 13608-66-7 CAPLUS
CN N,3'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]- (8CI) (CA INDEX NAME)



RN 13608-67-8 CAPLUS
CN N,3'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)- (8CI) (CA INDEX NAME)



RN 13608-68-9 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(m-2-imidazolin-2-ylphenyl)-
(8CI) (CA INDEX NAME)



RN 13608-72-5 CAPLUS
CN N,3'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)-,
dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 13608-73-6 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(m-2-imidazolin-2-ylphenyl)-,
dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 85 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1966:468119 CAPLUS
DN 65:68119
OREF 65:12723a-c
TI Polybasic compounds with a new mechanism of action against leukemia

AU Hirt, R.
CS Wander A.-G., Bern, Switz.
SO Intern. Congr. Chemotherapy, Proc., 3rd, Stuttgart, 1963 (**1964**), 2, 1055-8
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB The new title compds. usually had configurations of the general type represented by I. Data are given on the inhibitory action of 26 of these new compds. (out of a total of 600 synthesized) against Mycobacterium tuberculosis tested in vitro and the L 1210 strain of mouse leukemia tested in mice. The terminal R groups of the I were definitely basic (such as amidine, imidazoline, or guanidine moieties). Many of these compds. had a marked specific in vitro action against M. tuberculosis, whereas other bacteria were not affected by these compds. There was some correlation between the tuberculostatic action in vitro and the antileukemic action (prolongation of life) in mice. By conversion to derivs., the localization of these new compds. in cells could be demonstrated, fluorescing under uv light. The I were mainly localized in the nuclei of cells of warm-blooded animals (mice) and in equivalent portions of bacterial cells. Little of the I was demonstrable in the cytoplasm. Other expts. showed that I form complexes with nuclei acids, which may serve to explain their biol. action. However (in contrast to alkylating cytostatic agents) the I showed a rather low chemical reactivity. The I probably act by means of their high adsorptive power, so that at least the 1st stage of their biol. activity is of a physicochem. nature.
IT **13202-03-4**, Benzanilide, 4'-(2-imidazolin-2-yl)-4-(p-2-imidazolin-2-ylbenzamido)-
(antileukemic and tuberculocidic activity of)
RN 13202-03-4 CAPLUS
CN N,4'-Bibenzamide, 4-(2-imidazolin-2-yl)-N'-(p-2-imidazolin-2-ylphenyl)- (8CI) (CA INDEX NAME)



L5 ANSWER 86 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1966:78631 CAPLUS
DN 64:78631
OREF 64:14780h,14781a-c
TI Physiologic disposition of 4',4''-bis(1,4,5,6-tetrahydro-2-pyrimidinyl)terephthalanilide and 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-4'[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]carbamolylbenzanilide in dogs, monkeys, rats, and mice
AU Rogers, W. I.; Yesair, D. W.; Kensler, C. J.
CS Life Sci. Div., Arthur D. Little, Inc., Cambridge, MA
SO Journal of Pharmacology and Experimental Therapeutics (**1966**), 152(1), 139-50
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

AB Salient features of the physiologic disposition in animals of 2 orally active phthalanilide congeners were determined for comparison to the disposition of others which are not active against murine lymphocytic leukemias when administered orally, but which are highly active when administered intraperitoneally or intramuscularly. Drug concns. were determined mostly by spectrophotometry after direct chromatographic isolation from tissues and fluids or by acid displacement from specific complexes with phospholipids. A small fraction of drug was absorbed after oral administration to fasted rats, mice, dogs, and monkeys. The pattern of distribution of drug in tissues was similar after oral or intravenous administration. Kidneys had the highest drug concentration Neither drug could be detected in the blood 24 hrs. after injections. About 30% of each daily intravenous dose of 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-4'[[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]carbamoyl]benzanilide and 15 to 20% of each daily dose of 4,4''-bis(1,4,5,6-tetrahydro-2-pyrimidinyl)terephthalanilide was excreted in the urine. There was no evidence of metabolites which contained primary aromatic amines after strong acid hydrolysis.

IT **4675-50-7**, N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-
(in kidneys and urine after administration)

RN 4675-50-7 CAPLUS

CN Benzamide, 4-[[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)benzoyl]amino]-N-[4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 87 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1966:19374 CAPLUS

DN 64:19374

OREF 64:3556e-h,3557a-c

TI 3,5-Dioxo-1,2,4-triazolidines

IN Ruschig, Heinrich; Schmitt, Karl; Driesen, Gerd; Ther, Leopold; Pfaff, Werner

PA Farbwerke Hoechst A.-G.

SO 9 pp.

DT Patent

LA Unavailable

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 1200826		19650916	DE	19620113 <--

GI For diagram(s), see printed CA Issue.

AB β-Methoxycarbonylphydrazine-α-carbonyl chloride (22.8 g.) 17.5 g. p-cyclohexylaniline, and 12.1 g. PhNMe2 in 250 cc. EtOH was warmed 1 h. at 50-70°, 100 cc. 2N NaOH added, and the mixture warmed to a clear solution to give 1-phenyl-4-(p-cyclohexylphenyl)-3,5-dioxo-1,2,4-triazolidine, m. 166-8°. R, R1, M.p.; Ph, p-cyclohexylphenyl (II), 166-8° (H2O-EtOH); Ph, p-HOCH2CH2OC6H4, 172-3° (EtOH); Ph, p-EtC6H4, 162-3° (EtOH-H2O); Ph, p-tert-BuC6H4, 209-11°(EtOH); Ph, p,p'-C6H4CONHC6H4OEt, 246-50°

(HCOMe2-H2O); Ph, 3,5-(F3C)2C6H3, 175-7° (EtOH-H2O); Ph, p-Me2CH(CH2)5OC6H4, 109-10° (EtOH-H2O); Ph, p-BuC6H4, 113-15° (EtOH-H2O); Ph, p-iso-PrC6H4, 182-4° (EtOH); Ph, p-C8H17C6H4, 121-3° (EtOH); Ph, p-iso-AmC6H4, 123-4° (EtOH); 2,4-Me(MeO)C6H3, p-PhOC6H4, 172-4° (EtOH); Ph, p-PhCH2CH2C6H4, 133-6° (iso-PrOH); Ph, p-tert-AmC6H4, 179-80° (EtOH); Ph, m-F3CC6H4, 179-80° (EtOH); Ph, p-CH2:CHCH2OC6H4, 163-4° (MeOH); Ph, m-MeSC6H4, 160-2° (HCONMe2-H2O); Ph, p-EtOCH2CH2OC6H4, 159-61° (EtOH); Ph, p,p'-EtOC6H4OC6H4, 180-1° (EtOH-H2O); Ph, p-PhOCH2CH2OC6H4, 174-6° (EtOH); Ph, p-PhC6H4, 221-2°, (HCONMe2-EtOH); Ph, p-PhCH:CHC6H4, 200-2° (EtOH); Ph, p-C6H13SC6H4, 114-15° (EtOH-H2O); 3,4-Me2C6H3, 2,5-(AcNH)(C6H13O)C6H3, 215-18° (EtOH); Ph, p-α-pyridyloxyphenyl, 192-5° (MeOH); Ph, p-EtSC6H4, 156-7° (EtOH); Ph, p-BuSC6H4, 135-7° (EtOH-H2O); 2-C10H7, p-EtC6H4, 164-5° (EtOH); p-EtOC6H4, 3,5,4-Cl2(C6H13)C6H2, 142-5° (EtOH); 4,2,5-Cl(MeO)2C6H2, p-cyclohexylphenyl, 245-50° (decomposition); , , (EtOH-HCONMe2); Ph, m-O2NC6H4 (III), 264-6° (EtOH); Similarly were prepared the tabulated I. Hydrogenation of 20 g. III in MeOH with Raney Ni at room temperature gave 14.2 g. I (R = Ph, R1 = m-H2NC6H4), m. 195-7° (EtOH). The Na salt of II was obtained by heating II with the calculated amount of MeONa in iso-PrOH and cautious addition of Et2O. Similarly to the above method but with phenylhydrazine β-ethoxycarbonyl α-carbonyl chloride I (2nd table) were prepared R, R1, M.p.; Ph, p-PhOC6H4, 177-9° (EtOH); Ph, p-AcC6H4, 192-4° (EtOH); Ph, p-PhN:NC6H4, 250-3° (HCONMe2-EtOH); Ph, 3,4-(HO)(MeO2C)C6H3, 195-200° (MeOH); Ph, p-C6H4SO2NH2, 245-7° (from alkaline solution with 2N NaOH); Ph, 4,2-Me(2-ClC6H4NHSO2)C6H3, 173-5° (MeOH-H2O); Ph, p-C6H4CH:CHCO2H, 270-3° (EtOH); Ph, p-Et2NC6H4, 175-80° (EtOH); p-ClC6H4, p-Et2NC6H4, 207-10° (EtOH); p-ClC6H4, p-C6H4SO2NH2, 260-5°; Heating 25 g. Me 2-phenyl-4-[p-(β-chloroethoxy)phenyl]semicarbazide-1-carboxylate (m. 203-5°) with 3.7 g. MeONa in 150 cc. MeOH on a steam bath gave 20 g. I (R = Ph, R1 = p-ClCH2CH2OC5H4), m. 225-7° (HCONMe2-EtOH). Similarly obtained was I (R = Ph, R1 = p-BrCH2CH2C6H4), m. 156-8°, from the corresponding bromoethyl derivative (m. 197-9°). The compds. had anti inflammatory activity. Cf. preceding abstract

IT **4973-91-5**, p-Benzophenetidide, 4-(3,5-dioxo-1-phenyl-1,2,4-triazolidin-4-yl)-
(preparation of)

RN 4973-91-5 CAPLUS

CN p-Benzophenetidide, 4-(3,5-dioxo-1-phenyl-1,2,4-triazolidin-4-yl)- (7CI, 8CI) (CA INDEX NAME)



L5 ANSWER 88 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1965:502364 CAPLUS
DN 63:102364
OREF 63:18888h,18889a
TI Toxicology of antileukemic agents with special reference to phthalanilide derivatives
AU Kensler, C. J.; Palm, P. E.; Day, H. M.; Battista, S. P.; Rogers, W. I.; Yesair, D. W.; Wodinsky, I.
CS Arthur D. Little, Inc., Cambridge, MA
SO Cancer Research (**1965**), 25(9), 1622-37
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English
AB The toxicology of the antileukemic agents amethopterin, azaserine, 6-mercaptopurine, cyclophosphamide, mechlorethamine, cytoxan, 1-β-D-arabinofuranosylcytosine-HCl, 1-methyl-1-nitrosourea, 1-(2-chloroethyl)-1-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea, and phthalanilide derivs., such as 4',4'-di-2-imidazolin-2-ylterephthalanilide-2HCl, 4',4''-bis(2-imidazolin-2-ylamino)terephthalanilide-2HBr, 1,1'-m - phenylenebis [3 - [p - (2 - imidazolin - 2 - yl)phenyl] urea] - 2HCl, and N,N''-bis[p-(N'-methylamidino)phenyl]terephthalamidine-4HCl were studied for their toxicologic and therapeutic effects in normal mice and in mice bearing leukemia. Results indicate that the toxicologic problems may not be associated with structurally related compds. having antileukemic activity.
IT **4553-87-1**, N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride
(preparation of)
RN 4553-87-1 CAPLUS
CN N,4'-Bibenzamide, 4-(1,4,5,6-tetrahydro-2-pyrimidinyl)-N'-[p-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 89 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1950:42377 CAPLUS
DN 44:42377
OREF 44:8121c-i,8122a-b
TI Azo dyes
IN Straub, Fritz; Hanhart, Walter; Mannhart, Emil
PA CIBA Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2494416		19500110	US	<--

AB These azo dyes contain SO3H groups in the ortho position to the N:N group and are prepared from dyes derived from pyrazolone, which contains lake-forming groups which are capable of forming stable complex metal compds. The dyes are treated with metal-yielding agents either in substance, in the dye bath, or on the fiber. The dyes are especially fast to light. 4-Nitro-1-amino-2-benzenesulfonic acid 21.8 parts are diazotized and coupled with 1-(4-hydroxy-3-carboxyphenyl)-3-methyl-5-pyrazolone(I) 23.4. Crystalline Na2S 48 is added and the mixture heated to 60-5°. After neutralization with dilute HCl the dye is salted out, dissolved in H2O 1500, and AcONa 15 and p-NO2C6H4COCl 20 are added with stirring. The nitrobenzoylated dye is salted out, dissolved in H2O 2000, and neutralized; Na2S 48 is added and the mixture stirred for several hrs. at 60-5°. This dye is again salted out, dissolved in H2O, and converted to the urea derivative by treatment with COCl2 giving the dye 4,4'-bis{4-[1-(3-carboxy-4-hydroxyphenyl)-5-hydroxy-3-methyl-4-pyrazolylazo]-3-sulfophenylcarbamyl] carbanilide, which dyes cotton in the presence of Cu salts in yellow shades. 1-(4-Hydroxy-3-carboxyphenyl)-3-methyl-4-[4-(p-nitrobenzamido)-2-sulfophenylazo]-5-pyrazolol is converted to 4,4''-azobis{4'-[5-hydroxy-1-(4-hydroxy-3-carboxyphenyl)-3-methyl-4-pyrazolylazo]}bis[3'-sulfobenzanilide], which dyes cotton in the presence of Cu salts in fast yellow-brown shades. Bis(4'-amino-3'-sulfo-4-biphenylyl)urea and I give a similar dye. Tetrazotized 2,4-bis(4'-amino-3'-sulfo-4-biphenylyl)-6-anilino-s-triazine, prepared from 4,4'-diamino-3-biphenylsulfonic acid, aniline, and cyanuric chloride, is coupled with I to give brown-yellow shades on cotton. 1-Amino-4-nitro-2-benzenesulfonamide is diazotized and coupled with 4-[(3-carboxy-4-hydroxyphenyl)carbamylphenyl]-3-methyl-5-pyrazolone (II) and the dye treated with COCl2 to give 4,4'-bis{4-{1-[(3-carboxy-4-hydroxyphenyl)carbamylphenyl]-5-hydroxy-3-methyl-4-pyrazolyl}-3-sulfamyl}-carbanilide, which dyes cotton in the presence of Cu salts in orange-yellow shades. 4,4'-Diamino-3,3'-biphenyldisulfonic acid and I give 4,4'-(3,3'-disulfo-p-biphenylenebisazo)bis{[1-(4-hydroxy-3-

carboxyphenyl)]-3-methyl-5-pyrazolol}, which in the presence of Cu salts gives red-brown shades on cotton. 4,4'-Diamino-3,3'-biphenyldisulfonic acid is tetrazotized and coupled with II to give a dye which in the presence of Cu salts gives yellow-brown shades on cotton. 4-Amino-4'-hydroxy-3'-carboxy-1,1'-azobenzene-3-sulfonic acid and II give 4-[4-(3-carboxy-4-hydroxyphenylazo)-2-sulfophenylazo]-1-[4-(3-carboxy-4-hydroxyphenylcarbamyl)phenyl]-3-methyl-5-pyrazolol which gives brown-red shades on cotton in the presence of Cu salts. 4-(4'-Amino-3-sulfo-4-biphenylylazo)-1-(4-hydroxy-3-carboxyphenyl)-3-methyl-5-pyrazolol, prepared from 4-amino-4'-acetamido-3-biphenylsulfonic acid and I, and 4-{[4-(4-aminophenylcarbamyl)-2-sulfophenyl]azo}-1-(4-hydroxy-3-carboxyphenyl)-3-methyl-5-pyrazolol (III), prepared from diazotized 4-nitro-1-amino-2-benzenesulfonic acid and I, give 4-{4-[5-hydroxy-1-(3-carboxy-4-hydroxyphenyl)-3-methyl-4-pyrazolylazo)]-3-sulfophenyl}-4'-{4-[5-hydroxy-1-(3-carboxy-4-hydroxyphenyl)-3-methyl-4-pyrazolylazo]-3-sulfophenylcarbamyl}carbanilide which dyes cotton in the presence of Cu salts in fast yellow-brown shades. Diazotized 4-nitro-1-amino-2-benzenesulfonic acid coupled with I and this dye coupled with III and treated with COCl2 gives 4-[1-(3-carboxy-4-hydroxyphenyl)-5-hydroxy-3-methyl-4-pyrazolylazo]-4'-{4-[1-(3-carboxy-4-hydroxyphenyl)-5-hydroxy-3-methyl-4-pyrazolylazo]-3-sulfophenylcarbamyl}carbanilide, which with Cu salts gives brown-yellow shades on cotton.

IT **854243-20-2**, 3,3'-Biphenyldisulfonic acid, 4,4'-bis[1-[p-[(3-carboxy-4-hydroxyphenyl)carbamoyl]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]- **856189-36-1**, Metanilamide, N3,N3'-carbonylbis[6-[1-[p-[(3-carboxy-4-hydroxyphenyl)carbamoyl]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]- **860508-84-5**, Salicylic acid, 5-[p-[4-[4-(3-carboxy-4-hydroxyphenylazo)-2-sulfophenylazo]-3-methyl-5-oxo-2-pyrazolin-1-yl]benzamido]-
(preparation of)

RN 854243-20-2 CAPLUS

CN 3,3'-Biphenyldisulfonic acid, 4,4'-bis[1-[p-[(3-carboxy-4-hydroxyphenyl)carbamoyl]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 856189-36-1 CAPLUS
CN Metanilamide, N3,N3'-carbonylbis[6-[1-[p-[(3-carboxy-4-hydroxyphenyl)carbamoyl]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 860508-84-5 CAPLUS
CN Salicylic acid, 5-[p-[4-[4-(3-carboxy-4-hydroxyphenylazo)-2-sulfophenylazo]-3-methyl-5-oxo-2-pyrazolin-1-yl]benzamido]- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 90 OF 90 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1929:33344 CAPLUS
DN 23:33344
OREF 23:3909c-f
TI Arylamides of aromatic carboxylic and sulfonic acids
AU Heller, Kurt
SO Journal de Physiologie (Paris, 1946-1992) (**1929**), 121, 193-203

CODEN: JOPHAN; ISSN: 0021-7948
DT Journal
LA Unavailable
AB The arylsulfonamides were made from the sulfonyl chlorides and amines by heating with Na2CO3 and excess PhMe or C6H4Me2 (stirring). The NO2 groups were then reduced with Fe powder in hot dilute AcOH. In many cases the NH2 compds. were diazotized and reduced with Na2SO3 to hydrazines, which were then condensed with AcCH2CO2Et or BzCH2CO2Et to the corresponding pyrazolones. Many of the amides and pyrazolones gave promising azo dyes insol. in alkali (not described). The following new compds. are described: 1,5-H2NC10H6SO2NHPh, yellow, m. 171°; 1,8-, yellow, m. 139-40°; 1,4-, m. 190°; 1,7-, m. 146-7°; 1,6-, m. 127-8°; 1,5-AcOC10H6SO2Cl, m. 129°; 2,6-, m. 107°; 1,5-HOC10H6SO2NHPh, m. 200°; 2,6-, m. 104°; 2,4'-ClC5H4CONHC6H4NH2, m. 153°; 4,2'-NO2C6H4CONHC6H4Cl, m. 160°; 4,2'-NH2C6H4CONHC6H4Cl. m. 145°; 2,4,4'-(NO2)MeC6H2SO2NHC3H4OMe, m. 135°; 2,4,4'-(NH2)MeC6H2SO2NHC6NHC6H4OMe, m. 128°; 2,4,2'-(NH2)MeC6H2SO2NHC6H4OMe, gave a hydrazine-HCl, m. 196°, and from this a methylpyrazolone, m. 118°; in what follows, the values after each formula are resp. the m. ps. of the amine, the hydrazine HCl, and the methyl- and phenylpyrazolone derivs.: 2,4,4'-(NH2)MeC6H2SO2NHC6H4Me, 128°, 168°, 129°, -; 2,4,2'-(NH2)MeC6H2SO2NHC6H4Me, 148°, 199°, 116°, -; 2,3-NH2C10H6CONHPh, 192°, 110°, 179°, 186°; 2,3,2'-NH2C10H4CONHC10H7, 110°, 145°, 129°, 155°; 4,3'-NH2C6H4SO2NHC6H4NH2, -, 179-80°, 147°, 168°; 4-NH2C6H4CONHPh, -, 235°, 271°, -; 4-BzNHC6H4NH2, -, 273°, 233°, 268°; 4,2'-NH2C4H4CONHC6H4Cl, -, 180°, 231°, 238°; 2,3,4'-HOC10H4CONHC6H4NH2, -, 295°, 310°, 195°; 2,3,3'-,HOC10H6CONHC6H4NH2, -, 175°, 203-5°, 194°.
IT **860604-84-8**, Benzanilide, p-(4,5-dihydro-5-keto-3-methyl-1-pyrazolyl)-
(preparation of)
RN 860604-84-8 CAPLUS
CN Benzanilide, p-(4,5-dihydro-5-keto-3-methyl-1-pyrazolyl)- (3CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	448.29	609.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-65.70	-65.70

STN INTERNATIONAL LOGOFF AT 13:42:20 ON 16 NOV 2005